pmid	doi	title	Hugo_Symbol
35482846	10.1080/15548627.2022.2071382	Mutations in V-ATPase in follicular lymphoma activate autophagic flux creating a targetable dependency.	ATP6AP1
34791836	10.1002/cam4.4422	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	ATP6AP1
26691987	10.1038/ng.3473	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	ATP6AP1
25713363	10.1073/pnas.1501199112	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	ATP6AP1
34272611	10.1007/s00467-021-05202-9	Novel urine biomarkers to distinguish UTI from culture-negative pyuria.	CTSS
32396854	10.1016/j.ccell.2020.04.008	Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma.	CTSS
32330455	10.1016/j.ccell.2020.03.016	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma.	CTSS
32330423	10.1016/j.celrep.2020.107522	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.	CTSS
25907256	10.1007/s12253-015-9926-7	Exploring the Molecular Mechanism and Biomakers of Liver Cancer Based on Gene Expression Microarray.	CTSS
34624096	10.1182/blood.2020010405	ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells.	MEF2C
34440292	10.3390/genes12081118	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.	MEF2C
33298918	10.1038/s41467-020-20136-w	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	MEF2C
33150819	10.1080/08880018.2020.1838013	<i>KMT2A</i>-rearranged diffuse large B-cell lymphoma in a child: a case report and molecular characterization.	MEF2C
33094287	10.1093/narcan/zcaa029	Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma.	MEF2C
32913188	10.1038/s41419-020-02949-1	A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1<sup>-</sup> pre-B-ALL.	MEF2C
32142900	10.1016/j.jmoldx.2020.02.004	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia.	MEF2C
31900516	10.1007/s00210-019-01764-6	A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression.	MEF2C
30190342	10.3324/haematol.2018.196055	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.	MEF2C
30171027	10.3324/haematol.2017.186320	Clinical and molecular characteristics of <i>MEF2D</i> fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in <i>MEF2D-HNRNPH1</i> gene fusion.	MEF2C
29279377	10.1073/pnas.1717125115	Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.	MEF2C
28482719	10.1080/10428194.2017.1312383	MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.	MEF2C
27322685	10.18632/oncotarget.9982	Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia.	MEF2C
26957223	10.1038/mt.2016.55	Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.	MEF2C
26670384	10.1128/mBio.01863-15	Common Viral Integration Sites Identified in Avian Leukosis Virus-Induced B-Cell Lymphomas.	MEF2C
26473286	10.18632/oncotarget.5556	Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma.	MEF2C
26245647	10.1038/ncomms8953	MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.	MEF2C
26172269	10.1371/journal.pone.0132926	BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?	MEF2C
25716962		Analysis of microRNA expression in canine mammary cancer stem-like cells indicates epigenetic regulation of transforming growth factor-beta signaling.	MEF2C
25675295	10.1038/cddis.2014.594	The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.	MEF2C
24304814	10.1038/jid.2013.461	miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.	MEF2C
23975177	10.3324/haematol.2013.090233	Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.	MEF2C
22997707	10.1134/s1068162012030089	[The functional analysis of polymorphic insertions of Alu retroelements at acute lymphoblastic leukemia].	MEF2C
21481790	10.1016/j.ccr.2011.02.008	Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.	MEF2C
21425961	10.3109/10428194.2011.566391	Activation of Paired-homeobox gene PITX1 by del(5)(q31) in T-cell acute lymphoblastic leukemia.	MEF2C
21261500	10.3109/10428194.2010.537003	Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.	MEF2C
19056693	10.1182/blood-2007-09-113597	HOXA9 is required for survival in human MLL-rearranged acute leukemias.	MEF2C
18079734	10.1038/sj.leu.2405067	MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines.	MEF2C
16455055	10.1016/j.bbrc.2006.01.036	Evidence for the interaction of the regulatory protein Ki-1/57 with p53 and its interacting proteins.	MEF2C
28482719	10.1080/10428194.2017.1312383	MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.	MEF2C
26172269	10.1371/journal.pone.0132926	BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?	MEF2C
22997707	10.1134/s1068162012030089	[The functional analysis of polymorphic insertions of Alu retroelements at acute lymphoblastic leukemia].	MEF2C
21481790	10.1016/j.ccr.2011.02.008	Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.	MEF2C
18079734	10.1038/sj.leu.2405067	MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines.	MEF2C
34260908	10.1016/j.celrep.2021.109372	Inhibition of Rag GTPase signaling in mice suppresses B cell responses and lymphomagenesis with minimal detrimental trade-offs.	RRAGC
31579886	10.1038/s42255-019-0098-8	Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.	RRAGC
28659443	10.1126/scitranslmed.aak9969	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.	RRAGC
27267853	10.1158/1078-0432.CCR-16-0609	Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.	RRAGC
27230687	10.1038/ng0616-700b	Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	RRAGC
26691987	10.1038/ng.3473	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	RRAGC
35482846	10.1080/15548627.2022.2071382	Mutations in V-ATPase in follicular lymphoma activate autophagic flux creating a targetable dependency.	ATP6V1B2
30720463	10.1172/JCI98288	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.	ATP6V1B2
26691987	10.1038/ng.3473	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	ATP6V1B2
25713363	10.1073/pnas.1501199112	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	ATP6V1B2
36001451	10.1097/PAS.0000000000001956	Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.	ARID1A
35879731	10.1186/s40364-022-00401-4	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.	ARID1A
35794096	10.1038/s41467-022-31355-8	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	ARID1A
35727053	10.1002/cncr.34348	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.	ARID1A
35454811	10.3390/cancers14081904	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	ARID1A
35317330	10.14740/wjon1436	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	ARID1A
35172382	10.1002/JLB.5A0721-361R	Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic.	ARID1A
35054466	10.3390/life12010073	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.	ARID1A
35038193	10.1111/his.14617	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	ARID1A
34791836	10.1002/cam4.4422	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	ARID1A
34649275	10.1182/bloodadvances.2021005316	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.	ARID1A
34560683	10.1097/PAS.0000000000001813	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	ARID1A
34348985	10.1136/jclinpath-2021-207441	Clinicopathological characteristics and genetic variations of uterine tumours resembling ovarian sex cord tumours.	ARID1A
34265801	10.1097/PAS.0000000000001780	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	ARID1A
34070951	10.3390/diagnostics11060999	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.	ARID1A
34039950	10.1038/s41408-021-00493-5	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	ARID1A
33829512	10.1111/his.14378	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	ARID1A
33431788	10.1038/s41392-020-00437-8	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	ARID1A
33376237	10.1038/s41392-020-00331-3	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	ARID1A
33252851	10.1002/ctm2.221	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	ARID1A
32978169	10.1158/0008-5472.CAN-20-2147	EZH2-Targeted Therapies in Cancer: Hype or a Reality.	ARID1A
32918521	10.1002/pbc.28704	Aggressive Langerhans cell histiocytosis following T-cell acute lymphoblastic leukemia.	ARID1A
32083995	10.1200/JCO.19.02314	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.	ARID1A
31747604	10.1016/j.celrep.2019.10.083	Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.	ARID1A
31423576	10.1111/bjh.16159	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	ARID1A
31300419	10.1182/bloodadvances.2018029546	Sporadic and endemic Burkitt lymphoma have frequent <i>FOXO1</i> mutations but distinct hotspots in the AKT recognition motif.	ARID1A
31123138	10.1136/jclinpath-2019-205727	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis.	ARID1A
30886885	10.1016/j.gore.2019.02.007	Endometrial cancer arising after complete remission of uterine malignant lymphoma: A case report and mutation analysis.	ARID1A
30190015	10.1016/j.hoc.2018.05.007	Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	ARID1A
30134235	10.1159/000492835	Frequent Mutations in Natural Killer/T Cell Lymphoma.	ARID1A
29989027	10.18632/oncotarget.25601	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	ARID1A
29669287	10.1016/j.celrep.2018.03.078	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.	ARID1A
29486633	10.1177/1533034618754475	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.	ARID1A
29307627	10.1016/j.humpath.2017.12.025	Dedifferentiated liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant.	ARID1A
29222279	10.1182/asheducation-2017.1.358	Follicular lymphoma: are we ready for a risk-adapted approach?	ARID1A
29025291	10.1556/650.2017.30868	[Waldenström's macroglobulinemia and its individualized therapy options].	ARID1A
28401006		Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.	ARID1A
27872090	10.1158/0008-5472.CAN-16-1303	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.	ARID1A
27729836	10.5808/GI.2016.14.3.78	Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel.	ARID1A
27590521	10.18632/oncotarget.11773	Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.	ARID1A
27102345	10.1038/modpathol.2016.79	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	ARID1A
26839360	10.1136/thoraxjnl-2015-207950	A patient with complex multiple genomic ALK alterations.	ARID1A
26551670	10.1038/ng.3444	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	ARID1A
26473533	10.1038/bcj.2015.89	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	ARID1A
26468873	10.1371/journal.ppat.1005158	Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma.	ARID1A
26415585	10.1038/ncomms9470	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.	ARID1A
26256760	10.1016/S1470-2045(15)00169-2	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	ARID1A
26192917	10.1038/ng.3358	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.	ARID1A
25918285	10.1200/JCO.2014.59.2444	Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.	ARID1A
25779943	10.1158/1078-0432.CCR-14-2759	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.	ARID1A
25444907	10.1016/j.canlet.2014.11.024	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	ARID1A
24435047	10.1182/blood-2013-05-500264	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	ARID1A
24366360	10.1182/blood-2013-09-525808	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.	ARID1A
23292937	10.1073/pnas.1205299110	Genetic heterogeneity of diffuse large B-cell lymphoma.	ARID1A
23143597	10.1038/ng.2468	The genetic landscape of mutations in Burkitt lymphoma.	ARID1A
23091298	10.1182/blood-2012-06-437624	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.	ARID1A
22931316	10.1056/NEJMoa1200710	MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.	ARID1A
22915242	10.1007/s00428-012-1303-2	ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.	ARID1A
22585168	10.1158/2159-8290.CD-11-0208	Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.	ARID1A
21590771	10.1002/path.2911	Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.	ARID1A
19066270	10.1093/jnci/djn416	The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.	ARID1A
29486633	10.1177/1533034618754475	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.	ARID1A
22915242	10.1007/s00428-012-1303-2	ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.	ARID1A
24435047	10.1182/blood-2013-05-500264	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	ARID1A
26446488	10.1038/ncomms9325	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.	ARID1A
33891562	10.18632/aging.202903	Age-related differences of genetic susceptibility to patients with acute lymphoblastic leukemia.	ARID5B
33788417	10.1002/pbc.29036	Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene.	ARID5B
32488880	10.1002/jcla.23414	Association of TLX1 gene polymorphisms with the risk of acute lymphoblastic leukemia and B lineage acute lymphoblastic leukemia in Han Chinese children.	ARID5B
31870219	10.1080/08880018.2019.1705949	Association of <i>ABCC2</i> with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL).	ARID5B
31800539	10.1097/JCMA.0000000000000198	Reply to ""ARID5B rs7089424 and rs10994982 and association with B-lineage ALL susceptibility"".	ARID5B
31800538	10.1097/JCMA.0000000000000197	ARID5B rs7089424 and rs10994982 and association with B-lineage ALL susceptibility.	ARID5B
31704777	10.1136/jmedgenet-2019-106339	Novel phenotypes observed in patients with <i>ETV6</i>-linked leukaemia/familial thrombocytopenia syndrome and a biallelic <i>ARID5B</i> risk allele as leukaemogenic cofactor.	ARID5B
31573954	10.1158/1078-0432.CCR-19-0190	<i>ARID5B</i> Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia.	ARID5B
31424309	10.1080/08880018.2019.1649333	<i>ARID5B</i> rs10821936 and rs10994982 gene polymorphisms and acute lymphoblastic leukemia: relation to disease susceptibility and outcome.	ARID5B
31350265	10.1182/blood.2018890764	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.	ARID5B
31274788	10.1097/JCMA.0000000000000038	Genetic polymorphisms of ARID5B rs7089424 and rs10994982 are associated with B-lineage ALL susceptibility in Chinese pediatric population.	ARID5B
31227872	10.1007/s00277-019-03730-x	Variants in ARID5B gene are associated with the development of acute lymphoblastic leukemia in Mexican children.	ARID5B
31221981	10.1038/s12276-019-0230-6	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	ARID5B
31111395	10.1007/s12185-019-02658-2	ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis.	ARID5B
31076442	10.1182/blood.2018874503	The enhancer RNA <i>ARIEL</i> activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia.	ARID5B
30810385	10.1089/gtmb.2018.0283	Association of ARID5B and IKZF1 Variants with Leukemia from Northern India.	ARID5B
30770347	10.1158/1055-9965.EPI-18-0801	Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype.	ARID5B
29654272	10.1038/s41375-018-0110-4	Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.	ARID5B
29504848	10.1080/08916934.2018.1446525	Signalling pathways identified in salivary glands from primary Sjögren's syndrome patients reveal enhanced adipose tissue development.	ARID5B
29335448	10.1038/s41598-017-19127-7	Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese.	ARID5B
29326336	10.1101/gad.302646.117	ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.	ARID5B
28905228	10.1007/s12032-017-1038-7	Genetic susceptibility in childhood acute lymphoblastic leukemia.	ARID5B
28817678	10.1371/journal.pone.0180488	Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility.	ARID5B
28751478	10.1158/1055-9965.EPI-17-0360	Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Case-Control and Family-Based Studies in Multiethnic Populations.	ARID5B
28476190	10.1016/j.arcmed.2016.12.003	ARID5B, CEBPE and PIP4K2A Germline Genetic Polymorphisms and Risk of Childhood Acute Lymphoblastic Leukemia in Mexican Patients: A MIGICCL Study.	ARID5B
28381164	10.1177/1010428317697573	Association of ARID5B gene variants with acute lymphoblastic leukemia in Yemeni children.	ARID5B
28256501	10.1038/ncomms14616	Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10p21.2.	ARID5B
27644650		Association of Genetic Variants in ARID5B, IKZF1 and CEBPE with Risk of Childhood de novo B-Lineage Acute Lymphoblastic Leukemia in India.	ARID5B
27184773	10.3109/08880018.2016.1161685	Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence.	ARID5B
26941364	10.1158/1055-9965.EPI-15-0528	Pathway Analysis of Genome-wide Association Study in Childhood Leukemia among Hispanics.	ARID5B
26575185	10.1371/journal.pone.0143343	Somatic Mutation Allelic Ratio Test Using ddPCR (SMART-ddPCR): An Accurate Method for Assessment of Preferential Allelic Imbalance in Tumor DNA.	ARID5B
26104880	10.1038/ncomms8553	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.	ARID5B
25806972	10.1371/journal.pone.0121348	ARID5B, IKZF1 and non-genetic factors in the etiology of childhood acute lymphoblastic leukemia: the ESCALE study.	ARID5B
25761407	10.1007/s10552-015-0550-3	Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.	ARID5B
25310577	10.1371/journal.pone.0110255	Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures.	ARID5B
25297793		Genomic evaluations of childhood acute lymphoblastic leukemia susceptibility across race/ethnicities.	ARID5B
25150625	10.1016/j.bcmd.2014.07.011	Concordant B-cell precursor acute lymphoblastic leukemia in non-twinned siblings.	ARID5B
25124600	10.7314/apjcp.2014.15.15.6211	Associations between AT-rich interactive domain 5B gene polymorphisms and risk of childhood acute lymphoblastic leukemia: a meta-analysis.	ARID5B
25096228	10.1159/000363660	A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype.	ARID5B
25005032	10.3109/10428194.2014.933479	Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Münster Study Group.	ARID5B
24753091	10.1002/ajh.23727	Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B-cell acute lymphoblastic leukemia.	ARID5B
24712521	10.1111/bjh.12886	Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.	ARID5B
24707947	10.3109/10428194.2014.910662	Genetic markers in a multi-ethnic sample for childhood acute lymphoblastic leukemia risk.	ARID5B
24497567	10.3324/haematol.2013.090720	Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.	ARID5B
24200646	10.1016/j.bcmd.2013.10.003	High-resolution melting analyses for genetic variants in ARID5B and IKZF1 with childhood acute lymphoblastic leukemia susceptibility loci in Taiwan.	ARID5B
24013273	10.1007/s00432-013-1512-3	Intron 3 of the ARID5B gene: a hot spot for acute lymphoblastic leukemia susceptibility.	ARID5B
23975371	10.1007/s13277-013-1097-0	ARID5B gene rs10821936 polymorphism is associated with childhood acute lymphoblastic leukemia: a meta-analysis based on 39,116 subjects.	ARID5B
23836053	10.1007/s10552-013-0256-3	Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics.	ARID5B
23692655	10.1016/j.leukres.2013.04.022	ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.	ARID5B
23608171	10.1016/j.gene.2013.04.028	Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population.	ARID5B
23512250	10.1093/jnci/djt042	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.	ARID5B
23114164		[Research advances on correlation of ARID5B gene with childhood acute lymphoblastic leukemia - review].	ARID5B
23021489	10.1186/1755-8794-5-42	Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance.	ARID5B
23016962	10.1111/bjh.12063	Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study.	ARID5B
22422485	10.1002/pbc.24131	Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report.	ARID5B
22291082	10.1200/JCO.2011.38.0345	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.	ARID5B
21889209	10.1016/j.leukres.2011.07.034	Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.	ARID5B
21098271	10.1073/pnas.1006981107	Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.	ARID5B
20538337	10.1016/j.leukres.2010.05.013	Genetic variation and the risk of acute lymphoblastic leukemia.	ARID5B
20460642	10.3324/haematol.2010.022459	Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia.	ARID5B
20189245	10.1016/j.leukres.2010.02.001	Genome-wide association study of childhood acute lymphoblastic leukemia in Korea.	ARID5B
20054350	10.1038/leu.2009.277	ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence.	ARID5B
20042726	10.1182/blood-2009-09-241513	Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood.	ARID5B
19710713	10.1038/ng0909-957	Inherited susceptibility to pediatric acute lymphoblastic leukemia.	ARID5B
19684604	10.1038/ng.430	Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.	ARID5B
19684603	10.1038/ng.432	Germline genomic variants associated with childhood acute lymphoblastic leukemia.	ARID5B
31704777	10.1136/jmedgenet-2019-106339	Novel phenotypes observed in patients with <i>ETV6</i>-linked leukaemia/familial thrombocytopenia syndrome and a biallelic <i>ARID5B</i> risk allele as leukaemogenic cofactor.	ARID5B
30810385	10.1089/gtmb.2018.0283	Association of ARID5B and IKZF1 Variants with Leukemia from Northern India.	ARID5B
28476190	10.1016/j.arcmed.2016.12.003	ARID5B, CEBPE and PIP4K2A Germline Genetic Polymorphisms and Risk of Childhood Acute Lymphoblastic Leukemia in Mexican Patients: A MIGICCL Study.	ARID5B
27644650		Association of Genetic Variants in ARID5B, IKZF1 and CEBPE with Risk of Childhood de novo B-Lineage Acute Lymphoblastic Leukemia in India.	ARID5B
27184773	10.3109/08880018.2016.1161685	Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence.	ARID5B
25806972	10.1371/journal.pone.0121348	ARID5B, IKZF1 and non-genetic factors in the etiology of childhood acute lymphoblastic leukemia: the ESCALE study.	ARID5B
25761407	10.1007/s10552-015-0550-3	Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.	ARID5B
25310577	10.1371/journal.pone.0110255	Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures.	ARID5B
25005032	10.3109/10428194.2014.933479	Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Münster Study Group.	ARID5B
24497567	10.3324/haematol.2013.090720	Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.	ARID5B
23836053	10.1007/s10552-013-0256-3	Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics.	ARID5B
23692655	10.1016/j.leukres.2013.04.022	ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.	ARID5B
23608171	10.1016/j.gene.2013.04.028	Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population.	ARID5B
23016962	10.1111/bjh.12063	Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study.	ARID5B
22660188	10.1038/leu.2012.148	Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE).	ARID5B
21889209	10.1016/j.leukres.2011.07.034	Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.	ARID5B
20042726	10.1182/blood-2009-09-241513	Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood.	ARID5B
19684604	10.1038/ng.430	Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.	ARID5B
29326336	10.1101/gad.302646.117	ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.	ARID5B
26104880	10.1038/ncomms8553	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.	ARID5B
23996088	10.1182/blood-2013-03-491316	Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.	ARID5B
23512250	10.1093/jnci/djt042	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.	ARID5B
23382691	10.1371/journal.pgen.1003225	Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.	ARID5B
22076464	10.1038/leu.2011.302	Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.	ARID5B
19684603	10.1038/ng.432	Germline genomic variants associated with childhood acute lymphoblastic leukemia.	ARID5B
36094731	10.1007/s12104-022-10105-3	Assignment of IVL-Methyl side chain of the ligand-free monomeric human MALT1 paracaspase-IgL<sub>3</sub> domain in solution.	BCL10
35981904	10.1016/j.jaci.2022.06.023	The role of the CBM complex in allergic inflammation and disease.	BCL10
35929131	10.1158/2159-8290.CD-22-0614	BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine.	BCL10
35750252	10.1016/j.clim.2022.109067	BCL10 loss-of-function novel mutation leading to atypical severe combined immunodeficiency.	BCL10
35727133	10.7554/eLife.79826	A nucleation barrier spring-loads the CBM signalosome for binary activation.	BCL10
35658124	10.1158/2159-8290.CD-21-1566	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.	BCL10
35600392	10.3389/fonc.2022.881801	SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.	BCL10
35540095	10.1016/j.jacbts.2022.02.004	CARD9-Mediated Signaling and Cardiovascular Diseases.	BCL10
35411950	10.1002/cbf.3702	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	BCL10
35406516	10.3390/cancers14071742	Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment.	BCL10
35255409	10.1016/j.jbior.2022.100890	CARD11 signaling in regulatory T cell development and function.	BCL10
35230873	10.1126/scisignal.abk3083	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	BCL10
35218741	10.1016/j.bcp.2022.114977	Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.	BCL10
35192832	10.1016/j.scitotenv.2022.153990	Effects of gestational exposure to bisphenol A on the hepatic transcriptome and lipidome of rat dams: Intergenerational comparison of effects in the offspring.	BCL10
35099607	10.1007/s00018-022-04154-z	A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-κB signaling in activated T cells.	BCL10
34928543	10.1002/iub.2581	BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.	BCL10
34906687	10.1016/j.fsi.2021.12.009	BCL10 regulates the production of proinflammatory cytokines by activating MAPK-NF-κB/Rel signaling pathway in oysters.	BCL10
34879060	10.1371/journal.pntd.0010029	Deep resequencing identifies candidate functional genes in leprosy GWAS loci.	BCL10
34868072	10.3389/fimmu.2021.786572	Clinical and Immunological Features of Human BCL10 Deficiency.	BCL10
34826258	10.1126/sciimmunol.abi4425	Keratinocyte-intrinsic BCL10/MALT1 activity initiates and amplifies psoriasiform skin inflammation.	BCL10
34783281	10.1080/10428194.2021.1999444	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.	BCL10
34753803	10.1158/1541-7786.MCR-21-0208	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.	BCL10
34499781	10.1111/pin.13164	Primary pure pancreatic-type acinar cell carcinoma of the stomach.	BCL10
34481211	10.1016/j.prp.2021.153593	Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens.	BCL10
34412631	10.1186/s12935-021-02143-z	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.	BCL10
34236636	10.1007/978-1-0716-1669-7_8	Methods to Study CARD11-BCL10-MALT1 Dependent Canonical NF-κB Activation in Jurkat T Cells.	BCL10
34192836	10.1515/hsz-2021-0250	The paracaspase MALT1 in psoriasis.	BCL10
34014917	10.1371/journal.pcbi.1007986	Signaling through polymerization and degradation: Analysis and simulations of T cell activation mediated by Bcl10.	BCL10
33941870	10.1038/s41418-021-00787-y	USP12 promotes CD4<sup>+</sup> T cell responses through deubiquitinating and stabilizing BCL10.	BCL10
33872653	10.1016/j.jaci.2021.04.006	Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.	BCL10
33777778	10.3389/fonc.2021.628807	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	BCL10
33640899	10.1038/s41392-021-00477-8	TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO.	BCL10
33419765	10.4049/jimmunol.2001031	Intrinsic Abnormalities of Keratinocytes Initiate Skin Inflammation through the IL-23/T17 Axis in a MALT1-Dependent Manner.	BCL10
33329596	10.3389/fimmu.2020.601926	Cellular and Mathematical Analyses of LUBAC Involvement in T Cell Receptor-Mediated NF-κB Activation Pathway.	BCL10
33297339	10.3390/nu12123755	Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.	BCL10
33202260	10.1016/j.ajhg.2020.10.015	Multiplexed Functional Assessment of Genetic Variants in CARD11.	BCL10
33052237	10.7150/thno.47533	Targeting BCL10 by small peptides for the treatment of B cell lymphoma.	BCL10
32927162	10.1016/j.ecoenv.2020.111272	Augmented autophagy suppresses thymocytes development via Bcl10/p-p65 pathway in prenatal nicotine exposed fetal mice.	BCL10
32855441	10.1038/s41379-020-00660-2	Deciphering the genetic landscape of pulmonary lymphomas.	BCL10
32838054	10.1016/j.coemr.2020.07.011	Subcellular hot spots of GPCR signaling promote vascular inflammation.	BCL10
32790937	10.1111/febs.15522	Defining the combinatorial space of PKC::CARD-CC signal transduction nodes.	BCL10
32771677	10.1016/j.cellimm.2020.104189	The CBM complex: A growing multiplicity of cellular functions, regulatory mechanisms and connections to human disease.	BCL10
32768663	10.1016/j.cellimm.2020.104161	Bcl10 is associated with actin dynamics at the T cell immune synapse.	BCL10
32721634	10.1016/j.cellimm.2020.104158	Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist.	BCL10
32683230	10.1016/j.jtemb.2020.126615	Zinc homeostasis plays an important role in the prevention of obesity-induced cardiac inflammation, remodeling and dysfunction.	BCL10
32593012	10.1016/j.cellimm.2020.104147	Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease.	BCL10
32574386	10.1111/ejh.13467	MALT-1 as a novel therapeutic target for adult T-cell leukemia.	BCL10
32450431	10.1016/j.cellimm.2020.104133	The LUBAC participates in lysophosphatidic acid-induced NF-κB activation.	BCL10
32388054	10.1016/j.cellimm.2020.104115	TAK1 lessens the activity of the paracaspase MALT1 during T cell receptor signaling.	BCL10
32343482	10.15252/embr.201949237	MALT1 targeting suppresses CARD14-induced psoriatic dermatitis in mice.	BCL10
32179489	10.1016/j.cancergen.2020.02.005	Integrating transcriptome-wide association study and copy number variation study identifies candidate genes and pathways for diffuse non-Hodgkin's lymphoma.	BCL10
32164050	10.4143/crt.2019.606	Caspase Recruitment Domain Containing Protein 9 Suppresses Non-Small Cell Lung Cancer Proliferation and Invasion via Inhibiting MAPK/p38 Pathway.	BCL10
32012328	10.1002/hon.2718	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	BCL10
32008135	10.1007/s10875-020-00760-3	Human BCL10 Deficiency due to Homozygosity for a Rare Allele.	BCL10
31961340	10.1172/JCI97040	GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.	BCL10
31883669	10.1016/j.pathol.2019.09.014	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	BCL10
31808815	10.1093/cvr/cvz320	A complex role for Bcl10 in kidney injury.	BCL10
31757436	10.1016/j.pathol.2019.08.012	Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches.	BCL10
31751629	10.1016/j.dci.2019.103555	The signaling relations between three adaptors of porcine C-type lectin receptor pathway.	BCL10
31658764	10.3390/ijms20205022	B-Cell Activating Factor Enhances Hepatocyte-Driven Angiogenesis via B-Cell CLL/Lymphoma 10/Nuclear Factor-KappaB Signaling during Liver Regeneration.	BCL10
31644910	10.1016/j.celrep.2019.09.040	MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.	BCL10
31595055	10.1038/s41423-019-0297-y	Bcl10 is required for the development and suppressive function of Foxp3<sup>+</sup> regulatory T cells.	BCL10
31554683	10.1128/JVI.01499-19	Host CARD11 Inhibits Newcastle Disease Virus Replication by Suppressing Viral Polymerase Activity in Neurons.	BCL10
31427546		Characterisation of immunogenotypes of diffuse large B-cell lymphoma.	BCL10
31420608	10.1038/s41388-019-0958-4	MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.	BCL10
31391255	10.1074/jbc.RA119.009551	Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.	BCL10
31296852	10.1038/s41467-019-10953-z	Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation.	BCL10
31241148	10.1093/cvr/cvz169	B-cell lymphoma/leukaemia 10 and angiotensin II-induced kidney injury.	BCL10
31179345	10.1155/2019/9582714	Distinct Effects of Carrageenan and High-Fat Consumption on the Mechanisms of Insulin Resistance in Nonobese and Obese Models of Type 2 Diabetes.	BCL10
31178130	10.1016/j.bbrc.2019.06.004	ZNF436 promotes tumor cell proliferation through transcriptional activation of BCL10 in glioma.	BCL10
31138793	10.1038/s41467-019-10203-2	Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells.	BCL10
31092922	10.1038/s41586-019-1215-2	Targeting the CBM complex causes T<sub>reg</sub> cells to prime tumours for immune checkpoint therapy.	BCL10
31077220	10.1186/s13000-019-0815-3	Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.	BCL10
31060714	10.1016/j.jaci.2019.03.009	Germline CBM-opathies: From immunodeficiency to atopy.	BCL10
31047877	10.1016/j.cca.2019.04.077	BCL10 in cell survival after DNA damage.	BCL10
30773504	10.5582/bst.2018.01291	By regulating miR-182-5p/BCL10/CYCS, sufentanil reduces the apoptosis of umbilical cord mesenchymal stem cells caused by ropivacaine.	BCL10
30660642	10.1016/j.jaci.2018.12.1000	Double-strand break repair through homologous recombination in autosomal-recessive BCL10 deficiency.	BCL10
30553470	10.1016/j.cancergen.2018.08.001	Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.	BCL10
30515170	10.3389/fimmu.2018.02695	BCL10-CARD11 Fusion Mimics an Active CARD11 Seed That Triggers Constitutive BCL10 Oligomerization and Lymphocyte Activation.	BCL10
30514565	10.1016/j.cellimm.2018.11.001	Ubiquitination and phosphorylation of the CARD11-BCL10-MALT1 signalosome in T cells.	BCL10
30474008	10.3389/fonc.2018.00498	Post-translational Modifications of the CARMA1-BCL10-MALT1 Complex in Lymphocytes and Activated B-Cell Like Subtype of Diffuse Large B-Cell Lymphoma.	BCL10
30446641	10.1038/s41467-018-07215-9	Cellular metabolism constrains innate immune responses in early human ontogeny.	BCL10
30429846	10.3389/fimmu.2018.02366	A <i>CARD9</i> Founder Mutation Disrupts NF-κB Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation.	BCL10
30401751	10.1182/bloodadvances.2018022962	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.	BCL10
30386326	10.3389/fimmu.2018.02239	Clinical and Genetic Heterogeneity of <i>CARD14</i> Mutations in Psoriatic Skin Disease.	BCL10
30336982	10.1016/j.bbrc.2018.10.029	MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.	BCL10
30283447	10.3389/fimmu.2018.02105	Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease.	BCL10
30283440	10.3389/fimmu.2018.02078	The CBM-opathies-A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex.	BCL10
30279415	10.1038/s41467-018-06573-8	Molecular architecture and regulation of BCL10-MALT1 filaments.	BCL10
30214442	10.3389/fimmu.2018.01927	Holding All the CARDs: How MALT1 Controls CARMA/CARD-Dependent Signaling.	BCL10
30206119	10.1074/jbc.RA118.004821	Picomolar zinc binding modulates formation of Bcl10-nucleating assemblies of the caspase recruitment domain (CARD) of CARD9.	BCL10
30022982	10.3389/fimmu.2018.01539	BCL10 - Bridging CARDs to Immune Activation.	BCL10
29953499	10.1371/journal.pone.0199779	Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.	BCL10
29925955	10.1038/s41586-018-0290-0	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	BCL10
29881386	10.3389/fimmu.2018.01136	Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions.	BCL10
29765142	10.1038/s41379-018-0064-0	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.	BCL10
29649481	10.1016/j.bbrc.2018.04.057	Role of IκB kinase β in regulating the remodeling of the CARMA1-Bcl10-MALT1 complex.	BCL10
29382759	10.1073/pnas.1721967115	Assembly mechanism of the CARMA1-BCL10-MALT1-TRAF6 signalosome.	BCL10
29358699	10.1038/s41598-018-19822-z	GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.	BCL10
29340061	10.18632/oncotarget.22799	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.	BCL10
29289361	10.1016/j.blre.2017.12.001	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	BCL10
29259013	10.1158/0008-5472.CAN-17-1089	The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.	BCL10
29225710	10.1007/s12308-017-0302-2	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.	BCL10
29194363	10.3390/ijms18122581	The E3 Ubiquitin Ligase RNF7 Negatively Regulates CARD14/CARMA2sh Signaling.	BCL10
29084984	10.1038/s41598-017-14102-8	First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.	BCL10
28886618	10.1111/cmi.12788	Bcl10 synergistically links CEACAM3 and TLR-dependent inflammatory signalling.	BCL10
28765954	10.3892/mmr.2017.7116	In vitro reconstitution of interactions in the CARD9 signalosome.	BCL10
28717989	10.1007/s13238-017-0441-3	The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-κB activation and cell survival.	BCL10
28672935	10.3892/etm.2017.4464	Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.	BCL10
28288707	10.1016/j.beha.2016.09.002	MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism.	BCL10
28230860	10.1038/cddis.2017.51	CARMA2sh and ULK2 control pathogen-associated molecular patterns recognition in human keratinocytes: psoriasis-linked CARMA2sh mutants escape ULK2 censorship.	BCL10
28163398	10.1155/2017/8634865	<i>κ</i>-Carrageenan Enhances Lipopolysaccharide-Induced Interleukin-8 Secretion by Stimulating the Bcl10-NF-<i>κ</i>B Pathway in HT-29 Cells and Aggravates <i>C</i>. <i>freundii</i>-Induced Inflammation in Mice.	BCL10
28158919	10.1111/jcmm.13050	Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/p38 MAPK pathway.	BCL10
28052131	10.1371/journal.pone.0169026	Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation.	BCL10
27939769	10.1016/j.jid.2016.09.031	CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis.	BCL10
27873317	10.1002/path.4852	The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21).	BCL10
27864294	10.1182/blood-2016-05-718775	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.	BCL10
27860444	10.1002/dc.23634	Cytological findings and BCL10 expression in pancreatic acinar cell carcinoma: A Case Report.	BCL10
27777308	10.1074/jbc.M116.754028	Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.	BCL10
27681433	10.1016/j.celrep.2016.08.080	MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.	BCL10
27566587	10.18632/oncotarget.11548	Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	BCL10
27509941		E1/E2 of Hepatitis C Virus Genotype4 and Apoptosis.	BCL10
27452667	10.1016/j.semcancer.2016.07.003	MALT lymphoma: A paradigm of NF-κB dysregulation.	BCL10
27135977	10.1097/MOH.0000000000000257	Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.	BCL10
27109639	10.1016/j.clim.2016.04.011	Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.	BCL10
27092298	10.3389/fcimb.2016.00039	Mechanistic Insights into the Role of C-Type Lectin Receptor/CARD9 Signaling in Human Antifungal Immunity.	BCL10
27071417	10.1042/BCJ20160270	Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.	BCL10
27070702	10.1016/j.ccell.2016.03.006	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.	BCL10
27070692	10.1016/j.ccell.2016.03.018	Killing Lymphoma with Smac-Mimetics: As Easy as ABC?	BCL10
27006117	10.1242/jcs.185025	The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.	BCL10
26947079	10.1016/j.celrep.2016.02.031	CARMA3 Is a Host Factor Regulating the Balance of Inflammatory and Antiviral Responses against Viral Infection.	BCL10
26936881	10.4049/jimmunol.1403165	Usp9X Is Required for Lymphocyte Activation and Homeostasis through Its Control of ZAP70 Ubiquitination and PKCβ Kinase Activity.	BCL10
26884334	10.1074/jbc.M116.717322	Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.	BCL10
26776161	10.1038/onc.2015.493	Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.	BCL10
26774590	10.1016/j.clim.2016.01.003	Actin polymerisation after FCγR stimulation of human fibroblasts is BCL10 independent.	BCL10
26771713	10.1080/15384101.2015.1121322	BCL10 is recruited to sites of DNA damage to facilitate DNA double-strand break repair.	BCL10
26767426	10.1016/j.jid.2015.12.027	MALT1 Protease Activity Controls the Expression of Inflammatory Genes in Keratinocytes upon Zymosan Stimulation.	BCL10
26711259	10.1128/MCB.00876-15	Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.	BCL10
26668357	10.1073/pnas.1507459112	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.	BCL10
26615705	10.1016/j.anndiagpath.2015.10.001	Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma.	BCL10
26525107	10.1038/ncomms9777	The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling.	BCL10
26521038	10.1016/j.jaci.2015.09.016	Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians.	BCL10
26392569	10.1158/1541-7786.MCR-15-0229-T	The CBM Complex Underwrites NF-κB Activation to Promote HER2-Associated Tumor Malignancy.	BCL10
26354285	10.1002/hon.2251	Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.	BCL10
26287604	10.18632/oncotarget.4467	Immunodeficiency and CARD-BCL10-MALT1.	BCL10
26277595	10.1016/j.jaci.2015.06.031	Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.	BCL10
26202083	10.3892/ijmm.2015.2290	Bcl10 crucially nucleates the pro-apoptotic complexes comprising PDK1, PKCζ and caspase-3 at the nuclear envelope of etoposide-treated human cervical carcinoma C4-I cells.	BCL10
26043155	10.1080/15548627.2015.1055439	TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.	BCL10
26038114	10.15252/msb.20145880	Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation.	BCL10
25973362	10.1016/j.fob.2015.04.011	Oligomerized CARD16 promotes caspase-1 assembly and IL-1β processing.	BCL10
25965667	10.1371/journal.pone.0127083	MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses.	BCL10
25956014	10.1016/j.jaci.2015.02.037	Advances in basic and clinical immunology in 2014.	BCL10
25849213	10.1371/journal.pone.0122365	Functional characterization of zebrafish (Danio rerio) Bcl10.	BCL10
25748427	10.1371/journal.pone.0119363	MALT1-ubiquitination triggers non-genomic NF-κB/IKK signaling upon platelet activation.	BCL10
25736751	10.1007/978-1-4939-2422-6_12	Visualizing TCR-induced POLKADOTS formation and NF-κB activation in the D10 T-cell clone and mouse primary effector T cells.	BCL10
25556945	10.1016/j.chembiol.2014.10.021	Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas.	BCL10
25536807	10.2298/vsp130813035h	BCL10 aberations and NF-kappa B activation involving p65 are absent or rare in primary gastric MALT lymphoma.	BCL10
25391967	10.1007/s11060-014-1655-3	Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.	BCL10
25384343	10.1186/s40001-014-0062-8	Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.	BCL10
25365219	10.1172/JCI77493	Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity.	BCL10
25320244	10.1182/blood-2014-07-589689	Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.	BCL10
25245034	10.1186/s12964-014-0049-7	AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF-κB signaling upon T cell activation.	BCL10
25202022	10.1074/jbc.M114.588574	C-type lectin receptor dectin-3 mediates trehalose 6,6'-dimycolate (TDM)-induced Mincle expression through CARD9/Bcl10/MALT1-dependent nuclear factor (NF)-κB activation.	BCL10
25190756	10.1182/blood-2014-03-564609	Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice.	BCL10
25185129	10.1161/HYPERTENSIONAHA.114.04047	Linking angiotensin II to nuclear factor-κ light chain enhancer of activated B cells-induced cardiovascular damage: bad CARMAs.	BCL10
25185127	10.1161/HYPERTENSIONAHA.114.03900	Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.	BCL10
25150998	10.1007/978-1-4939-1212-4_8	Detection of NF-κB pathway activation in T helper cells.	BCL10
25105596	10.1371/journal.pone.0103774	MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.	BCL10
25087226	10.1016/j.jaci.2014.06.015	The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.	BCL10
25011391	10.1007/s00418-014-1244-8	Combining immunofluorescence with in situ proximity ligation assay: a novel imaging approach to monitor protein-protein interactions in relation to subcellular localization.	BCL10
24958727	10.1074/jbc.M114.588723	The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli.	BCL10
24917592	10.1126/scisignal.2005169	T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10.	BCL10
24825920	10.1126/scisignal.2004882	T cell receptor signals to NF-κB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome.	BCL10
24806599	10.1038/ncomms4755	An ITAM-Syk-CARD9 signalling axis triggers contact hypersensitivity by stimulating IL-1 production in dendritic cells.	BCL10
24792914	10.1016/j.immuni.2014.04.007	Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation.	BCL10
24777530	10.1038/ni.2888	Rad50-CARD9 interactions link cytosolic DNA sensing to IL-1β production.	BCL10
24732096	10.4161/cc.28707	BCL10 regulates RNF8/RNF168-mediated ubiquitination in the DNA damage response.	BCL10
24702227	10.3109/00016489.2013.878474	Increased expression of Dec-205, Bcl-10, Tim-3, and Trem-1 mRNA in chronic otitis media with cholesteatoma.	BCL10
24681956	10.1038/onc.2014.43	B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway.	BCL10
24641824	10.1016/j.bbagen.2014.03.011	Degraded λ-carrageenan activates NF-κB and AP-1 pathways in macrophages and enhances LPS-induced TNF-α secretion through AP-1.	BCL10
24633921	10.1007/s13277-014-1791-6	CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion.	BCL10
24560716	10.1016/j.imlet.2014.02.002	1999-2014: 15 years of BCL10.	BCL10
24548923	10.1016/j.molimm.2014.01.011	Phosphorylation of Carma1, but not Bcl10, by Akt regulates TCR/CD28-mediated NF-κB induction and cytokine production.	BCL10
24497531	10.1182/blood-2013-05-504019	A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells.	BCL10
24491438	10.1158/2159-8290.CD-13-0915	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.	BCL10
24443940	10.1111/cei.12275	CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response.	BCL10
24411492	10.1016/j.cytogfr.2013.12.008	The CBM signalosome: potential therapeutic target for aggressive lymphoma?	BCL10
24383645	10.1111/imm.12207	N-Ethyl-N-nitrosourea mutagenesis in the mouse provides strong genetic and in vivo evidence for the role of the Caspase Recruitment Domain (CARD) of CARD-MAGUK1 in T regulatory cell development.	BCL10
24375035	10.1002/jcp.24543	The three CARMA sisters: so different, so similar: a portrait of the three CARMA proteins and their involvement in human disorders.	BCL10
24329526	10.1089/dna.2013.2199	The TCR γδ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant Vδ1 and Vδ2 T cells.	BCL10
24145781	10.1038/ni.2737	ADAPted secretion of cytokines in NK cells.	BCL10
24074955	10.1016/j.molcel.2013.08.032	Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly.	BCL10
24036998	10.1038/ni.2708	Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells.	BCL10
24004675	10.1158/1078-0432.CCR-12-3869	Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.	BCL10
23918355	10.1073/pnas.1303669110	Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.	BCL10
23886693	10.1016/j.imbio.2013.06.013	Activation of NF-κB and respiratory burst following Aspergillus fumigatus stimulation of macrophages.	BCL10
23846624	10.14670/HH-29.77	BCL10 expression and localization in ocular adnexa MALT lymphomas: a comparative cytogenetic and immunohistochemical study.	BCL10
23827971	10.1016/j.pneurobio.2013.06.002	Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.	BCL10
23784377	10.1093/hmg/ddt286	An association study of TOLL and CARD with leprosy susceptibility in Chinese population.	BCL10
23770291	10.1016/j.cellsig.2013.06.007	Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders.	BCL10
23766559	10.1155/2013/397642	Carrageenan-induced colonic inflammation is reduced in Bcl10 null mice and increased in IL-10-deficient mice.	BCL10
23690623	10.1073/pnas.1221925110	Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex.	BCL10
23677497	10.1007/s13105-013-0259-2	Bcl10 is an essential regulator for A20 gene expression.	BCL10
23661444	10.4238/2013.April.12.6	Significance of Bcl10 gene mutations in the clinical diagnosis of MALT-type ocular adnexal lymphoma in the Chinese population.	BCL10
23632891	10.1182/blood-2012-12-470153	Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma.	BCL10
23616440	10.1002/glia.22502	Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB.	BCL10
23545653	10.1107/S1744309113005642	Crystallization and preliminary X-ray crystallographic studies of the CARD domain of human CARMA1.	BCL10
23530562	10.1111/pin.12045	BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.	BCL10
23525237	10.3892/ijmm.2013.1307	Self-oligomerization of the CARD domain prevents complex formation in the CARMA1 signalosome.	BCL10
23463379	10.1002/ijc.28148	Ca2+/calmodulin-dependent kinase II contributes to inhibitor of nuclear factor-kappa B kinase complex activation in Helicobacter pylori infection.	BCL10
23393199	10.1158/0008-5472.CAN-12-2362	Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.	BCL10
23297344	10.1128/MCB.06407-11	Kinase-independent feedback of the TAK1/TAB1 complex on BCL10 turnover and NF-κB activation.	BCL10
23252516	10.1111/bjh.12172	Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.	BCL10
23238011	10.1016/j.ccr.2012.11.011	A new ""brew"" of MALT1 inhibitors.	BCL10
23153494	10.1016/j.devcel.2012.09.021	The NF-κB signaling protein Bcl10 regulates actin dynamics by controlling AP1 and OCRL-bearing vesicles.	BCL10
23149938	10.1128/MCB.00850-12	A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.	BCL10
23087406	10.4049/jimmunol.1102952	Critical role of B cell lymphoma 10 in BAFF-regulated NF-κB activation and survival of anergic B cells.	BCL10
23035874	10.1186/1423-0127-19-85	BCL10GFP fusion protein as a substrate for analysis of determinants required for mucosa-associated lymphoid tissue 1 (MALT1)-mediated cleavage.	BCL10
22880103	10.1371/journal.pone.0042775	Structural insights into the assembly of CARMA1 and BCL10.	BCL10
22842723	10.3892/or.2012.1942	Breast MALT lymphomas: a clinicopathological and cytogenetic study of 9 cases.	BCL10
22818167	10.1016/j.humpath.2012.03.024	BCL10 down-regulation in peripheral T-cell lymphomas.	BCL10
22812606	10.1021/pr3000464	Role-shifting PKCζ fosters its own proapoptotic destruction by complexing with Bcl10 at the nuclear envelope of human cervical carcinoma cells: a proteomic and biochemical study.	BCL10
22734454	10.3109/10520295.2012.695025	BCL10 expression is unrelated to clinico-pathological parameters or prognoses for oral squamous cell carcinomas.	BCL10
22708078	10.1016/j.celrep.2012.04.006	Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance.	BCL10
22658522	10.1016/j.immuni.2012.04.008	Selective autophagy of the adaptor protein Bcl10 modulates T cell receptor activation of NF-κB.	BCL10
22579587	10.1016/j.bbadis.2012.05.001	Prolongation of carrageenan-induced inflammation in human colonic epithelial cells by activation of an NFκB-BCL10 loop.	BCL10
22574776	10.1042/BJ20120414	Protease activity of MALT1: a mystery unravelled.	BCL10
22564715	10.1016/j.ygyno.2012.04.047	Expression of BCL10 in cervical cancer has a role in the regulation of cell growth through the activation of NF-κB-dependent cyclin D1 signaling.	BCL10
22528498	10.1074/jbc.M111.335463	Protein kinase C-δ negatively regulates T cell receptor-induced NF-κB activation by inhibiting the assembly of CARMA1 signalosome.	BCL10
22474286	10.1074/jbc.M111.291708	Forkhead transcription factor FOXO3a protein activates nuclear factor κB through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation.	BCL10
22423967	10.1016/j.chom.2012.01.019	The autophagy regulator Rubicon is a feedback inhibitor of CARD9-mediated host innate immunity.	BCL10
22407319	10.1038/nature10894	The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response.	BCL10
22382892	10.1038/leu.2012.28	Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased VH4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment.	BCL10
22366302	10.1016/j.jmb.2012.02.018	Structural determinants of MALT1 protease activity.	BCL10
22363141	10.3748/wjg.v18.i7.685	Gastric mucosa-associated lymphoid tissue lymphomas and Helicobacter pylori infection: a Colombian perspective.	BCL10
22323537	10.4049/jimmunol.1101502	Cutting edge: the ""death"" adaptor CRADD/RAIDD targets BCL10 and suppresses agonist-induced cytokine expression in T lymphocytes.	BCL10
22158899	10.1073/pnas.1111708108	Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region.	BCL10
22079206	10.1016/j.jnutbio.2011.05.012	Molecular signature of kappa-carrageenan mimics chondroitin-4-sulfate and dermatan sulfate and enables interaction with arylsulfatase B.	BCL10
21988643	10.3109/10428194.2011.631157	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type.	BCL10
21954216	10.1002/pbc.23331	Inhibition of caspase-8 activity caused by overexpression of BCL10 contributes to the pathogenesis of high-grade MALT lymphoma.	BCL10
21896478	10.1074/jbc.M111.263384	The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-κB activation.	BCL10
21862580	10.1074/jbc.M111.259549	Akt fine-tunes NF-κB-dependent gene expression during T cell activation.	BCL10
21837708	10.1002/gcc.20910	Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter pylori-independent gastric MALT lymphoma.	BCL10
21750409	10.4161/cc.10.15.16923	From MALT lymphoma to the CBM signalosome: three decades of discovery.	BCL10
21745165	10.3109/10428194.2011.596968	Thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a clinicopathological and genetic analysis of six cases.	BCL10
21700900	10.1152/ajpgi.00071.2011	Specific effects of BCL10 Serine mutations on phosphorylations in canonical and noncanonical pathways of NF-κB activation following carrageenan.	BCL10
21674474	10.1002/eji.201041052	Dephosphorylation of Bcl-10 by calcineurin is essential for canonical NF-κB activation in Th cells.	BCL10
21513986	10.1016/j.molimm.2011.03.020	CaMKII targets Bcl10 in T-cell receptor induced activation of NF-κB.	BCL10
21489413	10.1016/j.cellimm.2011.03.025	CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells.	BCL10
21406399	10.1158/0008-5472.CAN-10-3626	CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression.	BCL10
21396111	10.1186/1478-811X-9-6	B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model.	BCL10
21283787	10.1371/journal.ppat.1001259	Selective C-Rel activation via Malt1 controls anti-fungal T(H)-17 immunity by dectin-1 and dectin-2.	BCL10
21261681	10.1111/j.1365-2559.2010.03699.x	MALT lymphoma: many roads lead to nuclear factor-κb activation.	BCL10
21199863	10.1074/jbc.M110.155895	The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation.	BCL10
21187856	10.1038/cr.2010.182	NF-κB signaling pathways regulated by CARMA family of scaffold proteins.	BCL10
21084243	10.1684/bdc.2010.1214	[Molecular abnormalities in lymphomas].	BCL10
21041303	10.1074/jbc.M110.158949	Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome.	BCL10
20937806	10.1074/jbc.M110.159681	Tumor necrosis factor alpha-induced inflammation is increased but apoptosis is inhibited by common food additive carrageenan.	BCL10
20830719	10.1002/ijc.25663	BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.	BCL10
20799731	10.1021/bi101052d	Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.	BCL10
20695076	10.4248/IJOS.09059	CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.	BCL10
20685844	10.1101/cshperspect.a003004	Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1.	BCL10
20679053		[Orbital and ocular adnexal lymphomas. Clinico-pathological correlation in 25 cases].	BCL10
20605784	10.1074/jbc.C110.109421	The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.	BCL10
20551178	10.1242/jcs.069476	Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation.	BCL10
20538615	10.1074/jbc.M110.131300	CARD9 mediates dectin-2-induced IkappaBalpha kinase ubiquitination leading to activation of NF-kappaB in response to stimulation by the hyphal form of Candida albicans.	BCL10
20520640	10.1038/leu.2010.118	Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism.	BCL10
20516126	10.1101/cshperspect.a000109	Oncogenic activation of NF-kappaB.	BCL10
20507572	10.1186/1471-2172-11-26	Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells.	BCL10
20466000	10.1016/j.yexcr.2010.05.004	Lipopolysaccharide-induced activation of NF-κB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.	BCL10
20439115	10.1016/j.molimm.2010.04.005	Interaction of calmodulin with Bcl10 modulates NF-kappaB activation.	BCL10
20431728	10.5009/gnl.2009.3.2.81	Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis.	BCL10
20235165	10.1002/path.2699	Interleukin-2 induces NF-kappaB activation through BCL10 and affects its subcellular localization in natural killer lymphoma cells.	BCL10
20193035	10.1111/j.1744-313X.2010.00898.x	BCL10 as a new candidate gene for immune response in pigs: cloning, expression and association analysis.	BCL10
22282688	10.2147/JBM.S9772	L-CBM signaling in lymphocyte development and function.	BCL10
19950170	10.1002/eji.200939445	c-Rel phenocopies PKCtheta but not Bcl-10 in regulating CD8+ T-cell activation versus tolerance.	BCL10
19915361		[Recent progress in lymphoma genomics and biology].	BCL10
19897720	10.1073/pnas.0907511106	Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.	BCL10
19897484	10.1074/jbc.M109.050815	B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation.	BCL10
19864123	10.1016/j.jnutbio.2009.07.002	Carrageenan-induced innate immune response is modified by enzymes that hydrolyze distinct galactosidic bonds.	BCL10
19860212		[Crucial roles of Helicobacter pylori infection in the pathogenesis of gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma].	BCL10
19841089	10.1084/jem.20091167	Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.	BCL10
19714753	10.1002/ibd.21092	Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent.	BCL10
19709433	10.1186/1476-4598-8-67	STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.	BCL10
19696203	10.1182/blood-2008-12-192583	Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.	BCL10
19690445	10.1159/000235603	BCL10 single nucleotide polymorphism and its association with CSF dissemination of primary intracranial germ cell tumors.	BCL10
19608748	10.1182/blood-2009-03-208215	Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma.	BCL10
19576081		[A clinical study of chromosome translocations in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Chinese patients].	BCL10
19538180	10.1042/BJ20090055	Generation and functional characterization of a BCL10-inhibitory peptide that represses NF-kappaB activation.	BCL10
19535128	10.1016/j.humpath.2009.02.018	Primary mucosa-associated lymphoid tissue lymphoma of the gallbladder: report of a case harboring API2/MALT1 gene fusion.	BCL10
19494296	10.4049/jimmunol.0803313	A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.	BCL10
19480824	10.1051/medsci/2009255454	[Role of CK1alpha in adaptive immunity and lymphomagenesis].	BCL10
19454668	10.4049/jimmunol.0900498	CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.	BCL10
19444310	10.1038/embor.2009.64	COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation.	BCL10
19428562	10.1016/j.imlet.2009.03.005	Barley-derived beta-D-glucan induces immunostimulation via a dectin-1-mediated pathway.	BCL10
19385974	10.1111/j.1349-7006.2009.01139.x	Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma.	BCL10
19366357	10.1111/j.1747-0285.2009.00805.x	Protein-protein interactions: a simple strategy to identify binding sites and peptide antagonists.	BCL10
19359218	10.1016/j.it.2009.03.002	CARD9 versus CARMA1 in innate and adaptive immunity.	BCL10
19309400	10.1111/j.1365-2559.2009.03250.x	Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF-kappaB in peripheral T-cell lymphomas and is associated with clinical outcome.	BCL10
19298243	10.1111/j.1600-0714.2009.00757.x	Nuclear BCL10 in primary Sjögren's syndrome.	BCL10
19279678	10.1371/journal.pone.0004822	Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.	BCL10
19174606	10.1159/000195698	Methylation of p16INK4A and mitotic arrest defective protein 2 (MAD2) genes in gastric marginal-zone B-cell lymphomas.	BCL10
19144384	10.1016/j.humpath.2008.06.032	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.	BCL10
19139169	10.1084/jem.20081445	Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation.	BCL10
19136564	10.1074/jbc.M806650200	Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells.	BCL10
19124758	10.4049/jimmunol.182.2.1146	Differential use of CARD9 by dectin-1 in macrophages and dendritic cells.	BCL10
19118383	10.1038/nature07613	Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.	BCL10
19112107	10.1074/jbc.C800207200	CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex.	BCL10
19085995	10.1002/ibd.20821	ROS, Hsp27, and IKKbeta mediate dextran sodium sulfate (DSS) activation of IkappaBa, NFkappaB, and IL-8.	BCL10
19080537		[High incidence of t (11; 18)/API2-MALT1 and BCL10 aberrant nuclear expression in pulmonary mucosa-associated lymphoid tissue lymphomas].	BCL10
19066953	10.1007/s00428-008-0710-x	The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.	BCL10
19035248		[Abnormal BCL10 nuclear expression and chromosomal translocation in ocular adnexal mucosa-associated lymphoid tissue lymphomas].	BCL10
18952491	10.1016/j.oraloncology.2008.08.003	Expression of BCL10 is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan.	BCL10
18949449	10.1007/s12185-008-0187-z	BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma.	BCL10
18941215	10.4049/jimmunol.181.9.6244	Loss of protein kinase C theta, Bcl10, or Malt1 selectively impairs proliferation and NF-kappa B activation in the CD4+ T cell subset.	BCL10
18927281	10.1158/1078-0432.CCR-08-0702	Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3.	BCL10
18833938		[Molecular genetics in primary gastrointestinal lymphomas].	BCL10
18829987	10.1093/intimm/dxn108	CD28 stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-Grb2/Gads axis.	BCL10
18806265	10.1074/jbc.M800670200	Multiple protein domains mediate interaction between Bcl10 and MALT1.	BCL10
18802088	10.4049/jimmunol.181.7.4840	Distinct regulation of integrin-dependent T cell conjugate formation and NF-kappa B activation by the adapter protein ADAP.	BCL10
18775860	10.1167/iovs.08-2539	Extranodal marginal zone lymphoma in the ocular region: clinical, immunophenotypical, and cytogenetical characteristics.	BCL10
18718996	10.1152/ajpgi.90434.2008	Lipopolysaccharide activates NF-kappaB by TLR4-Bcl10-dependent and independent pathways in colonic epithelial cells.	BCL10
18628489	10.1182/blood-2008-02-137513	Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma.	BCL10
18625728	10.1128/MCB.00418-08	The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.	BCL10
18606643	10.4049/jimmunol.181.2.918	Cell type-specific regulation of ITAM-mediated NF-kappaB activation by the adaptors, CARMA1 and CARD9.	BCL10
18583339	10.1074/jbc.M802344200	T cell receptor-mediated activation of CD4+CD44hi T cells bypasses Bcl10: an implication of differential NF-kappaB dependence of naïve and memory T cells during T cell receptor-mediated responses.	BCL10
18575460	10.1038/nri2338	Multifunctional roles for MALT1 in T-cell activation.	BCL10
18550498	10.3724/sp.j.1005.2008.00747	[In silico identification, molecular cloning and verification of a novel pig gene homologous to human BCL10 of innate immunity and its preliminary expression profiles in pigs].	BCL10
18452717	10.1016/j.bbagen.2008.03.019	Carrageenan-induced NFkappaB activation depends on distinct pathways mediated by reactive oxygen species and Hsp27 or by Bcl10.	BCL10
18445693	10.1158/1078-0432.CCR-07-4946	Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.	BCL10
18349075	10.1242/jcs.021105	A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB.	BCL10
18346354		[Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].	BCL10
18316375	10.1074/jbc.M707988200	Sequestration of NF-kappaB signaling complexes in lipid rafts contributes to repression of NF-kappaB in T lymphocytes under hyperthermia stress.	BCL10
18307945		[Significance of detection of Bcl-10 novel mutation in ocular adnexal mucosa-associated lymphoid tissue lymphoma].	BCL10
18307876		[Clonal relationship between transformed and non-transformed components in mucosa-associated lymphoid tissue lymphoma].	BCL10
18287044	10.1073/pnas.0712313105	NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation.	BCL10
18264101	10.1038/ni1568	The proteolytic activity of the paracaspase MALT1 is key in T cell activation.	BCL10
18252714	10.1074/jbc.M708833200	Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells.	BCL10
18245662	10.3324/haematol.11950	Rare occurrence of IgVH gene translocations and restricted IgVH gene repertoire in ocular MALT-type lymphoma.	BCL10
18231929	10.1080/10428190701784722	Analysis of CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma.	BCL10
18227156	10.1128/MCB.01505-07	T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.	BCL10
18192506	10.1182/blood-2007-11-123513	Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production.	BCL10
18175935	10.1248/bpb.31.13	Dissociation of Toll-like receptor 2-mediated innate immune response to Zymosan by organic solvent-treatment without loss of Dectin-1 reactivity.	BCL10
18086859	10.1084/jem.20070379	IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells.	BCL10
18040143	10.3960/jslrt.47.31	MALT lymphoma : recent advances in aetiology and molecular genetics.	BCL10
17948050	10.1038/sj.emboj.7601897	Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation.	BCL10
17893875	10.1002/ijc.23071	Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.	BCL10
17852708	10.1080/10428190701606818	Higher rates of t(11;18) in Chinese patients with transformed type of MALT lymphoma suggest novel pathways for progression of the disease.	BCL10
17845767		[Detection of t (11; 18) and rearrangement of bcl-10 in paraffin-embedded samples using interphase fluorescence in-situ hybridization].	BCL10
17785812	10.4049/jimmunol.179.6.3752	Bcl10 plays a divergent role in NK cell-mediated cytotoxicity and cytokine generation.	BCL10
17660823	10.1038/ni1493	MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit.	BCL10
17613665	10.1080/15321810701454573	Development, evaluation, and application of a highly sensitive microtiter plate ELISA for human Bcl10 protein.	BCL10
17540779	10.1152/ajpgi.00149.2007	Bcl10 mediates LPS-induced activation of NF-kappaB and IL-8 in human intestinal epithelial cells.	BCL10
17525089	10.1136/gut.2007.123729	Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation.	BCL10
17502353	10.1128/MCB.01645-06	Phosphorylation of Bcl10 negatively regulates T-cell receptor-mediated NF-kappaB activation.	BCL10
17478723	10.1126/science.1137895	Regulation of NF-kappaB activation in T cells via association of the adapter proteins ADAP and CARMA1.	BCL10
17473310	10.1126/stke.3842007pe21	CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB.	BCL10
17468049	10.1016/j.it.2007.04.004	Post-translational modifications regulate distinct functions of CARMA1 and BCL10.	BCL10
17462996	10.1074/jbc.M610610200	Caspase-8 and c-FLIPL associate in lipid rafts with NF-kappaB adaptors during T cell activation.	BCL10
17438001	10.1101/gad.1502507	CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation.	BCL10
17433222	10.1051/medsci/2007234353	[New Bcl10 regulation mechanisms: a step in the comprehension of what has occurred in MALT lymphomas?].	BCL10
17371994	10.4049/jimmunol.178.7.4373	Bcl10 controls TCR- and FcgammaR-induced actin polymerization.	BCL10
17363905	10.1038/sj.emboj.7601622	Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways.	BCL10
17356384	10.1097/01.jnen.0000248553.45456.96	Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.	BCL10
17317796	10.1354/vp.44-2-196	High-throughput immunophenotyping of 43 ferret lymphomas using tissue microarray technology.	BCL10
17287209	10.1074/jbc.M611038200	A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.	BCL10
17274374		[Expression of BCL-10 protein and the relationship with API2-MALT1 fusion gene in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue].	BCL10
17213322	10.1073/pnas.0606982104	Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.	BCL10
17202357	10.4049/jimmunol.178.2.953	Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection.	BCL10
17199743	10.1111/j.1440-1827.2007.02056.x	MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.	BCL10
17182539	10.4049/jimmunol.178.1.49	B cell lymphoma 10 is essential for FcepsilonR-mediated degranulation and IL-6 production in mast cells.	BCL10
17179215	10.1073/pnas.0601894104	Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors.	BCL10
17167822	10.1002/path.2117	Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression.	BCL10
17122510	10.1097/01.pas.0000213275.60962.2a	The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.	BCL10
17101977	10.1073/pnas.0601947103	CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.	BCL10
17099876	10.1002/cncr.22326	Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment.	BCL10
17098884	10.1136/jcp.2006.041012	Pulmonary mucosa-associated lymphoid tissue lymphoma with strong nuclear B-cell CLL/lymphoma 10 (BCL10) expression and novel translocation t(1;2)(p22;p12)/immunoglobulin kappa chain-BCL10.	BCL10
17095757	10.1152/ajpgi.00380.2006	Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells.	BCL10
17095601	10.1073/pnas.0608388103	Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production.	BCL10
17073595	10.2174/138945006778559256	The Bcl10/Malt1 signaling pathway as a drug target in lymphoma.	BCL10
17052756	10.1016/j.molimm.2006.09.012	Bcl10 is phosphorylated on Ser138 by Ca2+/calmodulin-dependent protein kinase II.	BCL10
17043017		CARMA1 and chromosomal translocations in extranodal marginal zone B-cell lymphomas of MALT type or diffuse large B-cell lymphomas.	BCL10
16920630	10.1016/j.cub.2006.06.062	Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation.	BCL10
16917511	10.1038/modpathol.3800668	MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast.	BCL10
16863911	10.1016/j.exphem.2006.06.003	The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.	BCL10
16862125	10.1038/nature04926	Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity.	BCL10
16831874	10.1074/jbc.M513057200	The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappaB from Toll-like receptor 4.	BCL10
16830336	10.1002/gcc.20352	Quantitative microsatellite analysis to delineate the commonly deleted region 1p22.3 in mantle cell lymphomas.	BCL10
16818229	10.1016/j.molcel.2006.05.027	Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation.	BCL10
16809782	10.1128/MCB.02469-05	Ca2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation.	BCL10
16799010	10.1167/iovs.05-1312	Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.	BCL10
16785131		BCL10 gene amplification associated with strong nuclear BCL10 expression in a diffuse large B cell lymphoma with IGH-BCL2 fusion.	BCL10
16784987	10.1016/j.humpath.2006.02.012	Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma.	BCL10
16776985		[Mucosa-associated lymphoid tissue lymphoma].	BCL10
16775419	10.4161/cc.5.13.2866	CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.	BCL10
16672958	10.1038/441032a	Cell biology: divining cancer cell weaknesses.	BCL10
16648871	10.1038/modpathol.3800597	Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival.	BCL10
16636680	10.1038/modpathol.3800609	Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation.	BCL10
16636337	10.1200/JCO.2006.05.6150	Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.	BCL10
16572204	10.1038/sj.leu.2404192	Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein.	BCL10
16572121	10.1038/nature04687	A loss-of-function RNA interference screen for molecular targets in cancer.	BCL10
16545185		[Expression of bcl-10 protein in MALT lymphoma].	BCL10
16512826	10.1111/j.1365-2141.2006.05969.x	Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21).	BCL10
16508008	10.1128/MCB.26.6.2327-2336.2006	CARMA1 is required for Akt-mediated NF-kappaB activation in T cells.	BCL10
16495340	10.1091/mbc.e05-10-0985	POLKADOTS are foci of functional interactions in T-Cell receptor-mediated signaling to NF-kappaB.	BCL10
16440771		[Long-term remission after CHOP therapy in a case of multifocal extranodal diffuse large B-cell lymphoma with t(1 ; 14) (p22 ; q32) and rearrangement of bcl-10].	BCL10
16432253	10.1084/jem.20051982	The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation.	BCL10
16395405	10.1172/JCI25641	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.	BCL10
16344587	10.1136/gut.2005.081117	Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication.	BCL10
16341151	10.1038/modpathol.3800523	MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells.	BCL10
16323006	10.1007/s00428-005-0122-0	Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases.	BCL10
16310461	10.1016/j.ajo.2005.05.038	BCL10 expression in ocular adnexal lymphomas.	BCL10
16280327	10.1074/jbc.M511014200	A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus.	BCL10
16229939	10.1016/j.canlet.2005.08.019	Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients.	BCL10
16177990	10.1002/cncr.21421	Overexpression of caspase recruitment domain (CARD) membrane-associated guanylate kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma.	BCL10
16155022	10.1200/JCO.2005.05.011	Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma.	BCL10
16127295	10.1159/000086789	Accumulation of BCL10 at the perinuclear region is required for the BCL10-mediated nuclear factor-kappa B activation.	BCL10
16123224	10.1182/blood-2004-12-4785	MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10.	BCL10
15989914	10.1016/j.amjmed.2005.02.004	Idiopathic retroperitoneal fibrosis associated with immunohematological abnormalities.	BCL10
15878976	10.1182/blood-2004-04-1248	Bcl10 can promote survival of antigen-stimulated B lymphocytes.	BCL10
15845895	10.1182/blood-2005-01-0004	Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21).	BCL10
15802604	10.1126/science.1107107	PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation.	BCL10
15802594	10.1126/science.1110902	Cell biology. Kinasing and clipping down the NF-kappa B trail.	BCL10
15711920	10.1007/s10495-005-6059-6	Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma.	BCL10
15703784	10.1038/sj.leu.2403644	T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.	BCL10
15694184	10.1016/j.beha.2004.08.003	Update on MALT lymphomas.	BCL10
15682443	10.1002/path.1715	MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.	BCL10
15682432	10.1002/path.1711	FISH analysis of MALT lymphoma-specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma.	BCL10
15637807	10.1016/j.febslet.2004.10.094	Inhibition of Bcl10-mediated activation of NF-kappa B by BinCARD, a Bcl10-interacting CARD protein.	BCL10
15634591		[Expression of BCL-10 in gastrointestinal mucosa-associated lymphoid tissue lymphoma].	BCL10
15598810	10.1182/blood-2004-06-2297	MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.	BCL10
15577674	10.1097/00000478-200412000-00003	Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion.	BCL10
15541657	10.1016/j.smim.2004.08.022	The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling.	BCL10
15540895	10.1532/ijh97.04101	Nuclear factor kappaB activation and antiapoptosis in mucosa-associated lymphoid tissue lymphoma.	BCL10
15539155	10.1016/j.immuni.2004.09.012	SAP regulates T(H)2 differentiation and PKC-theta-mediated activation of NF-kappaB1.	BCL10
15337797	10.1200/JCO.2004.10.087	Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas.	BCL10
15213237	10.1074/jbc.M400241200	BCL10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2.	BCL10
15210867	10.112/4.3.3	Ubiquitination for activation: new directions in the NF-kappaB roadmap.	BCL10
15207693	10.1016/j.bbrc.2004.05.112	Characterization of Bcl10 as a potential transcriptional activator that interacts with general transcription factor TFIIB.	BCL10
15202520	10.1080/10428190310001623793	Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma.	BCL10
15184390	10.1074/jbc.M402244200	Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator.	BCL10
15143341	10.1038/modpathol.3800164	t(1;14) and t(11;18) in the differential diagnosis of Waldenström's macroglobulinemia.	BCL10
15125833	10.1016/s1097-2765(04)00236-9	The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.	BCL10
15122200	10.1038/nri1352	CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.	BCL10
15100327	10.1093/jnci/djh138	Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation.	BCL10
15082780	10.1128/MCB.24.9.3860-3873.2004	Degradation of Bcl10 induced by T-cell activation negatively regulates NF-kappa B signaling.	BCL10
15070758	10.1073/pnas.0400885101	Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation.	BCL10
15049289	10.1016/j.it.2003.12.007	New roles for Bcl10 in B-cell development and LPS response.	BCL10
14993411	10.1124/mi.2.6.356	Determining the destiny of NF-kappa B after TCR ligation: it's CARMA1.	BCL10
14989765		[Expression of t(11;18) and bcl-10 in gastrointestinal MALT lymphoma].	BCL10
14754896	10.1074/jbc.M310599200	MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation.	BCL10
14724296	10.1073/pnas.0307858100	Complex and dynamic redistribution of NF-kappaB signaling intermediates in response to T cell receptor stimulation.	BCL10
14716524	10.1007/s10120-003-0260-5	Colliding gastric and intestinal phenotype well-differentiated adenocarcinoma of the stomach developing in an area of MALT-type lymphoma.	BCL10
14695475	10.1038/nature02273	Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO.	BCL10
14681324	10.1097/01.MP.0000097283.47637.58	API2-MALT1 fusion gene in colorectal lymphoma.	BCL10
14674990	10.1111/j.1440-1827.2004.01580.x	No evidence of a correlation between BCL10 expression and API2-MALT1 gene rearrangement in ocular adnexal MALT lymphoma.	BCL10
14673152	10.1128/MCB.24.1.164-171.2003	CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1.	BCL10
14657271	10.1242/jcs.00904	NF-kappaB signaling in lymphocytes: a new cast of characters.	BCL10
14645834	10.1126/science.1092951	Immunology. The paracaspase connection.	BCL10
14638696	10.1074/jbc.C300460200	Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-kappaB activation.	BCL10
14634131	10.4049/jimmunol.171.11.6154	Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation.	BCL10
14614861	10.1016/s1074-7613(03)00293-0	Differential requirement for Malt1 in T and B cell antigen receptor signaling.	BCL10
14576442	10.1126/science.1090769	Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase.	BCL10
14574335	10.1038/sj.leu.2403185	Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1.	BCL10
14523480	10.1038/sj.leu.2403128	BCL10 mutations are irrelevant to its aberrant nuclear localization in nasal NK/T-cell lymphoma.	BCL10
14502259	10.1038/sj.thj.6200295	T(11;18)(q21;q21) in gastric MALT lymphoma and diffuse large B-cell lymphoma of Chinese patients.	BCL10
12960515	10.1097/00001622-200309000-00001	Update: gastric MALT lymphoma.	BCL10
12950026	10.1002/path.1426	Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11;18) in primary cutaneous MALT-type lymphoma.	BCL10
12910267	10.1038/ni963	Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells.	BCL10
12909454	10.1016/s1471-4906(03)00177-7	TCR-induced NF-kappaB activation: a crucial role for Carma1, Bcl10 and MALT1.	BCL10
12900354	10.1182/blood-2003-04-1286	Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma.	BCL10
12883238	10.1097/00000478-200308000-00003	Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases.	BCL10
12867038	10.1016/s0960-9822(03)00491-3	Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation.	BCL10
12841349		Bcl10 protein can act as a transcription activator in yeast.	BCL10
12835267	10.1093/bioinformatics/btg148	Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values.	BCL10
12766579	10.1097/00000478-200306000-00006	Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases.	BCL10
12720128	10.1053/sonc.2003.50049	Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation.	BCL10
12692046	10.1136/gut.52.5.641	Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas.	BCL10
12676782	10.1182/blood-2002-11-3502	Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma.	BCL10
12651604	10.1016/S0002-9440(10)63908-9	API2-MALT1 fusion defines a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.	BCL10
12589800	10.1016/s0006-291x(03)00063-9	UV-light induces p38 MAPK-dependent phosphorylation of Bcl10.	BCL10
12517817	10.1182/blood-2002-10-3167	High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma.	BCL10
12393483	10.1182/blood-2002-07-2009	Cell cycle deregulation in B-cell lymphomas.	BCL10
12389689	10.1258/00222150260171605	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma.	BCL10
12154360	10.1038/ni830	CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation.	BCL10
12154356	10.1038/ni824	A requirement for CARMA1 in TCR-induced NF-kappa B activation.	BCL10
12091384	10.1074/jbc.M202222200	Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation induced by phorbol ester.	BCL10
12017308		Lack of BCL10 mRNA mutation in lymphold malignancies.	BCL10
11960389	10.1038/sj.thj.6200146	Genetic alterations underlying the pathogenesis of MALT lymphoma.	BCL10
11850073	10.1016/s0165-4608(01)00548-9	Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization.	BCL10
11836626		Lack of Bcl10 mutations in malignant cartilaginous tumors.	BCL10
11830492	10.1182/blood.v99.4.1398	BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression.	BCL10
11818074	10.1016/s0960-9822(01)00668-6	Bcl10.	BCL10
11780342		bcl 10 gene mutation in hepatocellular carcinoma.	BCL10
11753078	10.1097/00062752-200201000-00009	Mucosa-associated lymphoid tissue lymphoma.	BCL10
11748643	10.1002/path.1015	BCL10 in malignant lymphomas--an evaluation using fluorescence in situ hybridization.	BCL10
11722987	10.1182/asheducation-2001.1.241	MALT Lymphomas.	BCL10
11707622	10.1097/00125480-200111000-00001	Marginal-zone B-cell lymphoma of extranodal mucosa-associated lymphoid tissue type: molecular genetics provides new insights into pathogenesis.	BCL10
11701542	10.1182/asheducation-2000.1.180	Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma.	BCL10
11605060	10.3892/or.8.6.1333	Absence of Bcl10 gene mutations in Ewing's sarcomas.	BCL10
33640899	10.1038/s41392-021-00477-8	TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO.	BCL10
31774199	10.15252/embj.2019102030	Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis.	BCL10
31178130	10.1016/j.bbrc.2019.06.004	ZNF436 promotes tumor cell proliferation through transcriptional activation of BCL10 in glioma.	BCL10
30206119	10.1074/jbc.RA118.004821	Picomolar zinc binding modulates formation of Bcl10-nucleating assemblies of the caspase recruitment domain (CARD) of CARD9.	BCL10
25849213	10.1371/journal.pone.0122365	Functional characterization of zebrafish (Danio rerio) Bcl10.	BCL10
25105596	10.1371/journal.pone.0103774	MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.	BCL10
25011391	10.1007/s00418-014-1244-8	Combining immunofluorescence with in situ proximity ligation assay: a novel imaging approach to monitor protein-protein interactions in relation to subcellular localization.	BCL10
22812606	10.1021/pr3000464	Role-shifting PKCζ fosters its own proapoptotic destruction by complexing with Bcl10 at the nuclear envelope of human cervical carcinoma cells: a proteomic and biochemical study.	BCL10
22708078	10.1016/j.celrep.2012.04.006	Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance.	BCL10
22474286	10.1074/jbc.M111.291708	Forkhead transcription factor FOXO3a protein activates nuclear factor κB through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation.	BCL10
20439115	10.1016/j.molimm.2010.04.005	Interaction of calmodulin with Bcl10 modulates NF-kappaB activation.	BCL10
19309400	10.1111/j.1365-2559.2009.03250.x	Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF-kappaB in peripheral T-cell lymphomas and is associated with clinical outcome.	BCL10
19279678	10.1371/journal.pone.0004822	Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.	BCL10
18287044	10.1073/pnas.0712313105	NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation.	BCL10
17540779	10.1152/ajpgi.00149.2007	Bcl10 mediates LPS-induced activation of NF-kappaB and IL-8 in human intestinal epithelial cells.	BCL10
17371994	10.4049/jimmunol.178.7.4373	Bcl10 controls TCR- and FcgammaR-induced actin polymerization.	BCL10
17179215	10.1073/pnas.0601894104	Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors.	BCL10
17095757	10.1152/ajpgi.00380.2006	Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells.	BCL10
16809782	10.1128/MCB.02469-05	Ca2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation.	BCL10
16785131		BCL10 gene amplification associated with strong nuclear BCL10 expression in a diffuse large B cell lymphoma with IGH-BCL2 fusion.	BCL10
16341151	10.1038/modpathol.3800523	MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells.	BCL10
16127295	10.1159/000086789	Accumulation of BCL10 at the perinuclear region is required for the BCL10-mediated nuclear factor-kappa B activation.	BCL10
15878976	10.1182/blood-2004-04-1248	Bcl10 can promote survival of antigen-stimulated B lymphocytes.	BCL10
15637807	10.1016/j.febslet.2004.10.094	Inhibition of Bcl10-mediated activation of NF-kappa B by BinCARD, a Bcl10-interacting CARD protein.	BCL10
15082780	10.1128/MCB.24.9.3860-3873.2004	Degradation of Bcl10 induced by T-cell activation negatively regulates NF-kappa B signaling.	BCL10
11021819	10.1016/S0002-9440(10)64630-5	BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.	BCL10
10364242	10.1074/jbc.274.25.17946	CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis.	BCL10
10187770	10.1074/jbc.274.15.9955	CIPER, a novel NF kappaB-activating protein containing a caspase recruitment domain with homology to Herpesvirus-2 protein E10.	BCL10
9989495	10.1016/s0092-8674(00)80957-5	Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types.	BCL10
31296852	10.1038/s41467-019-10953-z	Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation.	BCL10
30514565	10.1016/j.cellimm.2018.11.001	Ubiquitination and phosphorylation of the CARD11-BCL10-MALT1 signalosome in T cells.	BCL10
30336982	10.1016/j.bbrc.2018.10.029	MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.	BCL10
30283440	10.3389/fimmu.2018.02078	The CBM-opathies-A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex.	BCL10
30279415	10.1038/s41467-018-06573-8	Molecular architecture and regulation of BCL10-MALT1 filaments.	BCL10
29953499	10.1371/journal.pone.0199779	Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.	BCL10
29382759	10.1073/pnas.1721967115	Assembly mechanism of the CARMA1-BCL10-MALT1-TRAF6 signalosome.	BCL10
29358699	10.1038/s41598-018-19822-z	GSK3β modulates NF-κB activation and RelB degradation through site-specific phosphorylation of BCL10.	BCL10
29259013	10.1158/0008-5472.CAN-17-1089	The CARMA3-Bcl10-MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.	BCL10
28765954	10.3892/mmr.2017.7116	In vitro reconstitution of interactions in the CARD9 signalosome.	BCL10
28717989	10.1007/s13238-017-0441-3	The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-κB activation and cell survival.	BCL10
27071417	10.1042/BCJ20160270	Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.	BCL10
25365219	10.1172/JCI77493	Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity.	BCL10
24074955	10.1016/j.molcel.2013.08.032	Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly.	BCL10
21406399	10.1158/0008-5472.CAN-10-3626	CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression.	BCL10
19709433	10.1186/1476-4598-8-67	STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.	BCL10
18349075	10.1242/jcs.021105	A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB.	BCL10
18231929	10.1080/10428190701784722	Analysis of CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma.	BCL10
17893875	10.1002/ijc.23071	Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.	BCL10
17502353	10.1128/MCB.01645-06	Phosphorylation of Bcl10 negatively regulates T-cell receptor-mediated NF-kappaB activation.	BCL10
17213322	10.1073/pnas.0606982104	Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.	BCL10
17199743	10.1111/j.1440-1827.2007.02056.x	MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.	BCL10
15207693	10.1016/j.bbrc.2004.05.112	Characterization of Bcl10 as a potential transcriptional activator that interacts with general transcription factor TFIIB.	BCL10
15122200	10.1038/nri1352	CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.	BCL10
11960389	10.1038/sj.thj.6200146	Genetic alterations underlying the pathogenesis of MALT lymphoma.	BCL10
11090634	10.1016/s1097-2765(00)00094-0	Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma.	BCL10
10187815	10.1074/jbc.274.15.10287	mE10, a novel caspase recruitment domain-containing proapoptotic molecule.	BCL10
10187771	10.1074/jbc.274.15.9962	Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase.	BCL10
31391255	10.1074/jbc.RA119.009551	Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.	BCL10
27113748	10.15252/embr.201642109	The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes.	BCL10
26038114	10.15252/msb.20145880	Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation.	BCL10
25569716	10.1038/ncomms6908	Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.	BCL10
25384343	10.1186/s40001-014-0062-8	Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.	BCL10
24732096	10.4161/cc.28707	BCL10 regulates RNF8/RNF168-mediated ubiquitination in the DNA damage response.	BCL10
24702227	10.3109/00016489.2013.878474	Increased expression of Dec-205, Bcl-10, Tim-3, and Trem-1 mRNA in chronic otitis media with cholesteatoma.	BCL10
24681956	10.1038/onc.2014.43	B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway.	BCL10
21674474	10.1002/eji.201041052	Dephosphorylation of Bcl-10 by calcineurin is essential for canonical NF-κB activation in Th cells.	BCL10
21513986	10.1016/j.molimm.2011.03.020	CaMKII targets Bcl10 in T-cell receptor induced activation of NF-κB.	BCL10
20695076	10.4248/IJOS.09059	CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.	BCL10
20551178	10.1242/jcs.069476	Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation.	BCL10
20466000	10.1016/j.yexcr.2010.05.004	Lipopolysaccharide-induced activation of NF-κB non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.	BCL10
19444310	10.1038/embor.2009.64	COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation.	BCL10
18806265	10.1074/jbc.M800670200	Multiple protein domains mediate interaction between Bcl10 and MALT1.	BCL10
17468049	10.1016/j.it.2007.04.004	Post-translational modifications regulate distinct functions of CARMA1 and BCL10.	BCL10
17052756	10.1016/j.molimm.2006.09.012	Bcl10 is phosphorylated on Ser138 by Ca2+/calmodulin-dependent protein kinase II.	BCL10
16920630	10.1016/j.cub.2006.06.062	Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation.	BCL10
16775419	10.4161/cc.5.13.2866	CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.	BCL10
16123224	10.1182/blood-2004-12-4785	MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10.	BCL10
14638696	10.1074/jbc.C300460200	Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-kappaB activation.	BCL10
12154360	10.1038/ni830	CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation.	BCL10
11466612	10.1038/sj.onc.1204576	Interchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signaling.	BCL10
11356195	10.1016/s0014-5793(01)02414-0	Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation.	BCL10
11262391	10.1074/jbc.M009984200	Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway.	BCL10
11238466	10.1083/jcb.152.5.1115	Equine herpesvirus protein E10 induces membrane recruitment and phosphorylation of its cellular homologue, bcl-10.	BCL10
11163238	10.1016/s0092-8674(01)00189-1	Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure.	BCL10
11053425	10.1074/jbc.C000726200	CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B.	BCL10
33329596	10.3389/fimmu.2020.601926	Cellular and Mathematical Analyses of LUBAC Involvement in T Cell Receptor-Mediated NF-κB Activation Pathway.	BCL10
31961340	10.1172/JCI97040	GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.	BCL10
27777308	10.1074/jbc.M116.754028	Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.	BCL10
27070702	10.1016/j.ccell.2016.03.006	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.	BCL10
23690623	10.1073/pnas.1221925110	Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex.	BCL10
23153494	10.1016/j.devcel.2012.09.021	The NF-κB signaling protein Bcl10 regulates actin dynamics by controlling AP1 and OCRL-bearing vesicles.	BCL10
22658522	10.1016/j.immuni.2012.04.008	Selective autophagy of the adaptor protein Bcl10 modulates T cell receptor activation of NF-κB.	BCL10
22528498	10.1074/jbc.M111.335463	Protein kinase C-δ negatively regulates T cell receptor-induced NF-κB activation by inhibiting the assembly of CARMA1 signalosome.	BCL10
19118383	10.1038/nature07613	Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.	BCL10
18252714	10.1074/jbc.M708833200	Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells.	BCL10
18223652	10.1038/ni1561	T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.	BCL10
17948050	10.1038/sj.emboj.7601897	Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation.	BCL10
17101977	10.1073/pnas.0601947103	CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.	BCL10
16395405	10.1172/JCI25641	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.	BCL10
16280327	10.1074/jbc.M511014200	A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus.	BCL10
15213237	10.1074/jbc.M400241200	BCL10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2.	BCL10
15184390	10.1074/jbc.M402244200	Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator.	BCL10
11387339	10.1074/jbc.M103824200	Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction.	BCL10
11278692	10.1074/jbc.M010512200	CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.	BCL10
11259443	10.1074/jbc.M102488200	Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B.	BCL10
10753917	10.1074/jbc.275.15.11114	Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein.	BCL10
10400625	10.1074/jbc.274.29.20127	c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappaB.	BCL10
35099607	10.1007/s00018-022-04154-z	A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-κB signaling in activated T cells.	BCL10
26711259	10.1128/MCB.00876-15	Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.	BCL10
26668357	10.1073/pnas.1507459112	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.	BCL10
25748427	10.1371/journal.pone.0119363	MALT1-ubiquitination triggers non-genomic NF-κB/IKK signaling upon platelet activation.	BCL10
21896478	10.1074/jbc.M111.263384	The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-κB activation.	BCL10
19897484	10.1074/jbc.M109.050815	B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation.	BCL10
19773279	10.1136/oem.2008.044024	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	BCL10
19573080	10.1111/j.1365-2141.2009.07790.x	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	BCL10
19336552	10.1158/1055-9965.EPI-08-1037	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	BCL10
19112107	10.1074/jbc.C800207200	CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex.	BCL10
18625728	10.1128/MCB.00418-08	The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.	BCL10
17363905	10.1038/sj.emboj.7601622	Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways.	BCL10
16831874	10.1074/jbc.M513057200	The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappaB from Toll-like receptor 4.	BCL10
15125833	10.1016/s1097-2765(04)00236-9	The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.	BCL10
14695475	10.1038/nature02273	Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO.	BCL10
35909289	10.2174/1568009622666220728123748	BCL11A Facilitates Cell Proliferation and Metastasis in Neuroblastoma via Regulating the PI3K/Akt Signaling Pathway.	BCL11A
35806029	10.3390/ijms23137025	LRF Promotes Indirectly Advantageous Chromatin Conformation via <i>BGLT3</i>-lncRNA Expression and Switch from Fetal to Adult Hemoglobin.	BCL11A
35805190	10.3390/cells11132106	Selective Ablation of BCL11A in Epidermal Keratinocytes Alters Skin Homeostasis and Accelerates Excisional Wound Healing In Vivo.	BCL11A
35504960	10.1038/s41598-022-11247-z	A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents.	BCL11A
35300055	10.2147/PGPM.S351599	Association Between Selected Single Nucleotide Polymorphisms in Globin and Related Genes and Response to Hydroxyurea Therapy in Ghanaian Children with Sickle Cell Disease.	BCL11A
35143940	10.1016/j.gene.2022.146289	Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia.	BCL11A
34611409	10.2147/OTT.S319845	Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report.	BCL11A
34592153	10.1016/j.celrep.2021.109759	Structural basis for human ZBTB7A action at the fetal globin promoter.	BCL11A
33959502	10.3389/fonc.2021.638897	c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	BCL11A
33910976	10.1126/scitranslmed.abb0411	Sustained fetal hemoglobin induction in vivo is achieved by <i>BCL11A</i> interference and coexpressed truncated erythropoietin receptor.	BCL11A
33154494	10.1038/s41598-020-76157-4	The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution.	BCL11A
33073380	10.1111/bjh.17102	F cell numbers are associated with an X-linked genetic polymorphism and correlate with haematological parameters in patients with sickle cell disease.	BCL11A
32903878	10.1159/000508566	A Novel de novo Frameshift Mutation in the <i>BCL11A</i> Gene in a Patient with Intellectual Disability Syndrome and Epilepsy.	BCL11A
32882024	10.1093/jnci/djaa133	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children.	BCL11A
32878504	10.1080/03630269.2020.1811117	Association Between Genetic Polymorphisms and Hb F Levels in Heterozygous β-Thalassemia 3.5 kb Deletions.	BCL11A
32625084	10.3389/fphar.2020.00820	BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer/T-Cell Lymphoma.	BCL11A
32576660	10.1074/jbc.RA120.014018	The transcriptional repressor BCL11A promotes breast cancer metastasis.	BCL11A
32319565	10.3892/ijo.2020.4995	miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.	BCL11A
32266150	10.3389/fonc.2020.00375	BCL11A Promotes the Progression of Laryngeal Squamous Cell Carcinoma.	BCL11A
32218847	10.3892/ol.2020.11383	BCL11A confers cell invasion and migration in androgen receptor-positive triple-negative breast cancer.	BCL11A
32085444	10.3390/ani10020317	Metabolic and Biomolecular Changes Induced by Incremental Long-Term Training in Young Thoroughbred Racehorses during First Workout Season.	BCL11A
32013807	10.1177/1010428319901061	Antiproliferative and proapoptotic effects of <i>Inula viscosa</i> extract on Burkitt lymphoma cell line.	BCL11A
31654056	10.1042/BSR20190604	BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases.	BCL11A
31410080	10.3906/biy-1810-2	Systematic analysis of the frequently amplified 2p15-p16.1 locus reveals PAPOLG as a potential proto-oncogene in follicular and transformed follicular lymphoma.	BCL11A
31362654	10.2174/1389450120666190726155733	Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.	BCL11A
31312380		Molecular simulation studies on B-cell lymphoma/leukaemia 11A (BCL11A).	BCL11A
31277480	10.3390/cancers11070941	The Unsolved Puzzle of c-Rel in B Cell Lymphoma.	BCL11A
31039344	10.1016/j.ejphar.2019.04.042	Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.	BCL11A
31000522	10.1158/0008-5472.CAN-18-3438	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.	BCL11A
30870006	10.1096/fj.201802252R	Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.	BCL11A
30853596	10.1016/j.ygeno.2019.03.002	Identification of deleterious SNPs and their effects on BCL11A, the master regulator of fetal hemoglobin expression.	BCL11A
30821197	10.1080/03630269.2018.1515774	BCL11A Down-Regulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells.	BCL11A
30768627	10.1371/journal.pone.0212492	The rs61742690 (S783N) single nucleotide polymorphism is a suitable target for disrupting BCL11A-mediated foetal-to-adult globin switching.	BCL11A
30520249	10.1111/1753-0407.12882	Role of metabolic syndrome and its components as mediators of the genetic effect on type 2 diabetes: A family-based study in China.	BCL11A
30289070	10.2174/1566524018666181004121604	Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in β-Thalassemia Patients.	BCL11A
30124006	10.22074/cellj.2019.5589	Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction.	BCL11A
29975921	10.1159/000491526	MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.	BCL11A
31938433		Clinical significance of BCL11A expression in ER-negative and PR-negative endometrial carcinoma.	BCL11A
29581848	10.18632/oncotarget.24512	Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma.	BCL11A
29018799	10.3389/fmed.2017.00153	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform.	BCL11A
28544358	10.1111/ajco.12690	The expression pattern of Bcl11a, Mdm2 and Pten genes in B-cell acute lymphoblastic leukemia.	BCL11A
28493377	10.1002/eji.201646621	Neonatal myeloid derived suppressor cells show reduced apoptosis and immunosuppressive activity upon infection with Escherichia coli.	BCL11A
28404650	10.1183/13993003.02149-2016	Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient.	BCL11A
28225775	10.1371/journal.pone.0171116	Genetic polymorphisms and plasma levels of BCL11A contribute to the development of laryngeal squamous cell carcinoma.	BCL11A
27835906	10.18632/oncotarget.13239	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.	BCL11A
27786413	10.1002/pbc.26251	DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.	BCL11A
27774950		[Knock-down of BCL11A expression in breast cancer cells promotes MDA-MB-231 cell apoptosis].	BCL11A
27653684	10.1016/j.celrep.2016.08.064	Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype.	BCL11A
27340226	10.1093/hmg/ddw170	Hemoglobin genetics: recent contributions of GWAS and gene editing.	BCL11A
26862517	10.22074/cellj.2016.3808	MicroRNA Expression in β-Thalassemia and Sickle Cell Disease: A Role in The Induction of Fetal Hemoglobin.	BCL11A
26487345	10.1038/srep15215	Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell.	BCL11A
26342260	10.1016/j.exphem.2015.08.011	Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin.	BCL11A
25979662	10.1016/j.ejmg.2015.04.006	Brain malformations in a patient with deletion 2p16.1: A refinement of the phenotype to BCL11A.	BCL11A
25364581	10.7497/j.issn.2095-3941.2014.03.006	The gene expression patterns of BMPR2, EP300, TGFβ2, and TNFAIP3 in B-Lymphoma cells.	BCL11A
25044937	10.1002/cbin.10332	Gene expression profile analysis of SUDHL6 cells with siRNA-mediated BCL11A downregulation.	BCL11A
24961604	10.1186/2047-783X-19-34	Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells.	BCL11A
24832791	10.1002/gcc.22184	Amplification of 2p as a genomic marker for transformation in lymphoma.	BCL11A
24796653	10.1111/1753-0407.12163	Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients 1miR-146.	BCL11A
24344258	10.1073/pnas.1321704111	Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.	BCL11A
23815911	10.7534/j.issn.1009-2137.2013.03.018	[Effect of BCL11A gene on transcription of γ-globin gene].	BCL11A
23758992	10.1186/1476-4598-12-61	BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification.	BCL11A
23432949	10.1179/1607845413Y.0000000078	Concurrent rearrangements of BCL2, BCL3, and BCL11A genes in atypical chronic lymphocytic leukemia.	BCL11A
23361909	10.1182/blood-2012-06-434530	Erythropoiesis and globin switching in compound Klf1::Bcl11a mutant mice.	BCL11A
24648892	10.3892/br.2012.9	Downregulation of BCL11A by siRNA induces apoptosis in B lymphoma cell lines.	BCL11A
22890838	10.1002/ijc.27774	High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.	BCL11A
22582156	10.1007/s13205-011-0026-4	Comparative studies of glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1: evidence for a eutherian mammalian origin for the GPIHBP1 gene from an LY6-like gene.	BCL11A
21822207	10.1038/modpathol.2011.116	Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.	BCL11A
21772954	10.4081/pr.2011.e17	Recent advances in β-thalassemias.	BCL11A
21429398		[Preliminary study of gene expression profile associated with risk classification of childhood patients with acute lymphoblastic leukemia].	BCL11A
21366467	10.5858/2009-0463-RSR.1	Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma.	BCL11A
20623620	10.1002/jnr.22407	X-linked mental retardation gene CASK interacts with Bcl11A/CTIP1 and regulates axon branching and outgrowth.	BCL11A
20578197	10.1002/ajh.21758	14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a.	BCL11A
20534004	10.1111/j.1471-4159.2010.06852.x	Bcl11A/CTIP1 mediates the effect of the glutamate receptor on axon branching and dendrite outgrowth.	BCL11A
19369625	10.1309/AJCPXLY46UPFLISC	Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes.	BCL11A
19096012	10.1182/blood-2008-07-168096	Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.	BCL11A
18940474	10.1016/j.cancergencyto.2008.06.007	BCL2 and BCL3 are recurrent translocation partners of the IGH locus.	BCL11A
18367492	10.3324/haematol.12221	Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia.	BCL11A
18253030	10.1159/000112062	U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma.	BCL11A
17638669	10.1309/21TN2RUWKR827UW2	Chronic lymphocytic leukemia FISH panel: impact on diagnosis.	BCL11A
17230227	10.1038/sj.leu.2404529	Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas.	BCL11A
16871282	10.1038/sj.leu.2404324	Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.	BCL11A
16734728	10.1111/j.1349-7006.2006.00209.x	Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma.	BCL11A
16704730	10.1186/1476-4598-5-18	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.	BCL11A
15496980	10.1038/sj.leu.2403500	Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.	BCL11A
15337798	10.1200/JCO.2004.11.025	Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas.	BCL11A
15313894	10.1158/0008-5472.CAN-04-1253	Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.	BCL11A
15241441	10.1038/labinvest.3700152	Epstein-Barr virus is integrated between REL and BCL-11A in American Burkitt lymphoma cell line (NAB-2).	BCL11A
12774917	10.1007/BF02982637	The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies.	BCL11A
12406872	10.1182/blood-2002-07-2119	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations.	BCL11A
12040429	10.1038/sj.leu.2402528	The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia.	BCL11A
11986957	10.1038/sj.leu.2402480	Lack of somatic hypermutation of IG V(H) genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene.	BCL11A
11830502	10.1182/blood.v99.4.1474	Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.	BCL11A
11719382	10.1182/blood.v98.12.3413	The BCL11 gene family: involvement of BCL11A in lymphoid malignancies.	BCL11A
20578197	10.1002/ajh.21758	14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a.	BCL11A
19369625	10.1309/AJCPXLY46UPFLISC	Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes.	BCL11A
16871282	10.1038/sj.leu.2404324	Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.	BCL11A
16704730	10.1186/1476-4598-5-18	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.	BCL11A
11986957	10.1038/sj.leu.2402480	Lack of somatic hypermutation of IG V(H) genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene.	BCL11A
32319565	10.3892/ijo.2020.4995	miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.	BCL11A
30520249	10.1111/1753-0407.12882	Role of metabolic syndrome and its components as mediators of the genetic effect on type 2 diabetes: A family-based study in China.	BCL11A
29975921	10.1159/000491526	MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.	BCL11A
28544358	10.1111/ajco.12690	The expression pattern of Bcl11a, Mdm2 and Pten genes in B-cell acute lymphoblastic leukemia.	BCL11A
23758992	10.1186/1476-4598-12-61	BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification.	BCL11A
11830502	10.1182/blood.v99.4.1474	Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.	BCL11A
20623620	10.1002/jnr.22407	X-linked mental retardation gene CASK interacts with Bcl11A/CTIP1 and regulates axon branching and outgrowth.	BCL11A
16091750	10.1038/sj.onc.1208904	BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter.	BCL11A
11719382	10.1182/blood.v98.12.3413	The BCL11 gene family: involvement of BCL11A in lymphoid malignancies.	BCL11A
16147992	10.1074/mcp.M500112-MCP200	Analysis of BCL6-interacting proteins by tandem mass spectrometry.	BCL11A
33809641	10.3390/cancers13061340	Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.	BIRC6
32961552	10.1182/blood.2020007507	Mutational landscape of gray zone lymphoma.	BIRC6
30931701	10.1080/15384101.2019.1601477	circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis.	BIRC6
27343444	10.1016/j.jtho.2016.06.001	Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.	BIRC6
27614248	10.1016/j.jtho.2016.08.145	Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.	BIRC6
26001147	10.1097/JTO.0000000000000467	BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.	BIRC6
23678170	10.1128/JVI.03159-12	Epstein-Barr virus-encoded microRNA BART15-3p promotes cell apoptosis partially by targeting BRUCE.	BIRC6
21902653	10.2174/156652411797536723	Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.	BIRC6
19759907	10.1371/journal.pone.0007089	High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma.	BIRC6
34653294	10.1111/cas.15164	C/EBPβ induces B-cell acute lymphoblastic leukemia and cooperates with BLNK mutations.	BLNK
33570628	10.1182/bloodadvances.2020001665	Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.	BLNK
33416167	10.3892/or.2020.7888	Involvement of Blnk and Foxo1 in tumor suppression in BCR‑ABL1‑transformed pro‑B cells.	BLNK
33020271	10.1073/pnas.2007946117	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	BLNK
32585766	10.1002/1878-0261.12753	Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.	BLNK
32420699	10.1002/cam4.3136	Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.	BLNK
31882553	10.21873/cgp.20169	BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.	BLNK
30890517	10.12122/j.issn.1673-4254.2019.02.20	[Structure and function of B-cell linker and its role in the development of B cell-related diseases].	BLNK
30872780	10.1038/s41375-019-0442-8	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	BLNK
30402490	10.1155/2018/6728128	Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion.	BLNK
29931583	10.1007/s10637-018-0623-8	Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.	BLNK
28972016	10.1182/blood-2017-06-743252	Philadelphia chromosome-like acute lymphoblastic leukemia.	BLNK
28791394	10.3892/mmr.2017.7158	Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.	BLNK
28476192	10.1016/j.arcmed.2016.12.005	Gene Expression Profiling of Acute Lymphoblastic Leukemia in Children with Very Early Relapse.	BLNK
28369050	10.1038/ni.3716	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.	BLNK
27016671	10.1016/j.molimm.2016.03.007	PAX5 promotes pre-B cell proliferation by regulating the expression of pre-B cell receptor and its downstream signaling.	BLNK
26703467	10.1074/jbc.M115.637835	B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.	BLNK
26522721	10.1038/onc.2015.385	ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway.	BLNK
26354285	10.1002/hon.2251	Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.	BLNK
25391967	10.1007/s11060-014-1655-3	Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.	BLNK
25080849	10.1111/ejh.12427	B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.	BLNK
24240734	10.1007/s00401-013-1202-x	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.	BLNK
24169826	10.1182/blood-2012-12-473090	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.	BLNK
23066158	10.4049/jimmunol.1201440	Highly restricted usage of Ig H chain VH14 family gene segments in Slp65-deficient pre-B cell leukemia in mice.	BLNK
22956576	10.4049/jimmunol.1201267	Regulation of B cell linker protein transcription by PU.1 and Spi-B in murine B cell acute lymphoblastic leukemia.	BLNK
22880054	10.1371/journal.pone.0042610	Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.	BLNK
22262777	10.1182/blood-2011-04-351965	CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells.	BLNK
20876806	10.1158/0008-5472.CAN-10-1438	Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia.	BLNK
19855081	10.1182/blood-2009-02-204362	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.	BLNK
19850008	10.1016/j.bbrc.2009.10.070	Phosphatidylinositol-3-kinase-dependent phosphorylation of SLP-76 by the lymphoma-associated ITK-SYK fusion-protein.	BLNK
19758698	10.1016/j.leukres.2009.08.030	Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.	BLNK
19150402	10.1016/j.cellsig.2008.12.006	SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux.	BLNK
19047679	10.1182/blood-2008-07-166355	BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.	BLNK
18566961	10.1002/path.2384	The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype.	BLNK
18426802	10.1074/jbc.M708459200	Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.	BLNK
18172310	10.1158/0008-5472.CAN-07-2778	PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.	BLNK
18006696	10.1182/blood-2007-07-100115	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.	BLNK
17717600	10.1172/JCI30842	B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.	BLNK
16888096	10.1182/blood-2006-03-013821	Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.	BLNK
16636677	10.1038/sj.onc.1209520	SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.	BLNK
16568084	10.1038/sj.onc.1209510	The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.	BLNK
15744341	10.1038/sj.leu.2403702	Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma.	BLNK
15231650	10.1158/0008-5472.CAN-03-3885	High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas.	BLNK
15029213	10.1038/sj.leu.2403349	Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia.	BLNK
14984504	10.1111/j.1365-2141.2004.04802.x	Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples.	BLNK
12881301	10.1182/blood-2003-05-1487	Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease.	BLNK
12761551	10.1038/nature01608	Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia.	BLNK
12436112	10.1038/ni862	The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion.	BLNK
10498607		Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.	BLNK
11489945	10.1084/jem.194.3.255	Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.	BLNK
9341187	10.1074/jbc.272.43.27362	Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase Cgamma, Grb2, and Vav after B cell antigen receptor activation.	BLNK
36078155	10.3390/cells11172747	Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.	BTK
36068158	10.1016/j.clml.2022.07.017	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.	BTK
36051079	10.1002/jha2.428	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	BTK
36051027	10.1002/jha2.489	Inactivating <i>BTK</i> mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with <i>BCL2</i> translocation.	BTK
36035991	10.3389/fcell.2022.935023	Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.	BTK
36029150	10.1002/cpdd.1153	Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.	BTK
36029036	10.1111/bjh.18418	Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.	BTK
36003901	10.2147/BLCTT.S259860	Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.	BTK
35999205	10.1038/s41408-022-00720-7	Determining drug dose in the era of targeted therapies: playing it (un)safe?	BTK
35979372	10.3389/fimmu.2022.943354	Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.	BTK
35975476	10.1002/hon.3056	Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.	BTK
35973369	10.1016/j.intimp.2022.109138	Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.	BTK
35957865	10.3389/fonc.2022.941633	Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review.	BTK
35956064	10.3390/jcm11154447	Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group.	BTK
35941532	10.1186/s10020-022-00518-0	Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.	BTK
35937468	10.6004/jadpro.2022.13.5.14	A Focus on Waldenström Macroglobulinemia and AL Amyloidosis.	BTK
35911566	10.2147/BLCTT.S326627	Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.	BTK
35908982	10.1016/j.blre.2022.100992	Follicular lymphoma: The long and winding road leading to your cure?	BTK
35852229	10.1080/10428194.2022.2098289	Practical management of chronic lymphocytic leukemia with acalabrutinib.	BTK
35836543	10.21037/tcr-22-1375	A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy.	BTK
35804999	10.3390/cancers14133229	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.	BTK
35785180	10.3389/fonc.2022.901797	Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.	BTK
35770040	10.2147/TCRM.S338655	Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.	BTK
35757723	10.3389/fimmu.2022.894787	Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.	BTK
35745866	10.3390/pharmaceutics14061294	Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.	BTK
35721157	10.3389/fphar.2022.864194	HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.	BTK
35714675	10.6004/jnccn.2022.0031	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.	BTK
35680835	10.19746/j.cnki.issn.1009-2137.2022.03.049	[Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review].	BTK
35671249	10.1021/acs.jmedchem.2c00324	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.	BTK
35670706	10.1358/dot.2022.58.6.3378055	Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.	BTK
35658124	10.1158/2159-8290.CD-21-1566	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.	BTK
35651781	10.1177/20406207221093980	Zanubrutinib in lymphoproliferative disorders: a comprehensive review.	BTK
35639332	10.1007/s11912-022-01297-x	Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.	BTK
35628381	10.3390/ijms23105570	<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.	BTK
35597428	10.1016/j.cellsig.2022.110358	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.	BTK
35596920	10.1007/s11912-022-01286-0	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.	BTK
35577753	10.1016/j.clml.2022.04.017	SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.	BTK
35571529	10.1155/2022/1930546	Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.	BTK
35561314	10.1182/bloodadvances.2022007247	Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.	BTK
35558005	10.1177/17588359221093745	Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.	BTK
35510210	10.1177/20406207221093962	Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.	BTK
35482146	10.1007/s11307-022-01733-1	[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase.	BTK
35474969	10.1097/HS9.0000000000000715	New Mechanisms of Genomic Escape From Noncovalent BTK Inhibitors.	BTK
35465824	10.1080/10428194.2022.2064995	The role of BTK inhibitors on the tumor microenvironment in CLL.	BTK
35450208	10.1177/20406207221090886	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	BTK
35440579	10.1038/s41467-022-29835-y	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.	BTK
35437106	10.1080/17474086.2022.2067526	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.	BTK
35435617	10.1007/s11864-022-00953-5	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	BTK
35411950	10.1002/cbf.3702	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	BTK
35411248		PIK-75 overcomes venetoclax resistance <i>via</i> blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.	BTK
35404729	10.1080/14737140.2022.2064849	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.	BTK
35403972	10.1007/s11912-022-01250-y	Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.	BTK
35383885	10.1111/bjh.18162	A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.	BTK
35379357	10.1186/s40364-022-00357-5	Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.	BTK
35357653	10.1007/s11864-022-00974-0	New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.	BTK
35356629	10.3389/fphar.2021.812565	Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals.	BTK
35350909	10.1177/10781552221090869	Real-world management of targeted therapies in chronic lymphocytic leukemia.	BTK
35341452	10.1080/10428194.2022.2056179	Incidence of <i>Pneumocystis jirovecii</i> pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis.	BTK
35339405	10.1016/j.clml.2022.02.005	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.	BTK
35330376	10.3390/jpm12030376	Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.	BTK
35326604	10.3390/cancers14061453	DLBCL 1L-What to Expect beyond R-CHOP?	BTK
35313381	10.1002/hon.2986	Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.	BTK
35306909	10.1177/10781552221087730	A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström's macroglobulinemia.	BTK
35306137	10.1016/j.cellsig.2022.110311	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	BTK
35303070	10.1182/blood.2021014162	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.	BTK
35296646	10.1038/s41419-022-04684-1	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	BTK
35294723	10.1007/s11864-022-00973-1	Novel Approaches for the Treatment of Patients with Richter's Syndrome.	BTK
35273899	10.1055/s-0042-1744128	Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib.	BTK
35266562	10.1002/ajh.26523	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	BTK
35255496	10.1182/bloodadvances.2021006147	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	BTK
35247800	10.1016/j.thromres.2022.02.020	The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.	BTK
35247223	10.1002/hon.2983	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.	BTK
35237395	10.1177/20406207221080738	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).	BTK
35230873	10.1126/scisignal.abk3083	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	BTK
35205606	10.3390/cancers14040860	Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.	BTK
35196427	10.1056/NEJMoa2114110	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.	BTK
35188143	10.1358/dot.2022.58.2.3360405	Research progress in overcoming ibrutinib drug resistance.	BTK
35184664	10.1080/17474086.2022.2044778	Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy.	BTK
35169086	10.11477/mf.1436204531	[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].	BTK
35149375	10.1016/j.ctarc.2022.100527	Current approach to Waldenström Macroglobulinemia.	BTK
35139644	10.2217/fon-2021-0602	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.	BTK
35123927	10.1016/j.clml.2022.01.008	SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.	BTK
35116520	10.21037/tcr-21-50	Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.	BTK
35115740	10.1007/s12288-021-01433-w	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study.	BTK
35096069	10.1155/2022/1182384	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).	BTK
35087759	10.3389/fonc.2021.801124	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.	BTK
35078814	10.1158/0008-5472.CAN-21-0218	Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.	BTK
35076567	10.3390/neurolint14010009	Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.	BTK
35068379	10.1080/16078454.2021.2019363	Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.	BTK
35031886	10.1186/s43556-021-00066-9	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	BTK
35003920	10.7717/peerj.12571	Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway.	BTK
34993136	10.3389/fonc.2021.771669	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.	BTK
34980578	10.1016/j.clml.2021.11.014	SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.	BTK
34970462	10.1155/2021/3964465	Reactivation of <i>Coccidioides immitis</i> in a Prosthetic Knee after Initiation of Chemotherapy.	BTK
34932207	10.1007/s40265-021-01657-0	Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.	BTK
34910982	10.1016/j.bioorg.2021.105541	Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.	BTK
34905129	10.1007/s11523-021-00857-8	Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.	BTK
34887877	10.3389/fimmu.2021.804735	Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors.	BTK
34884478	10.3390/ijms222312673	BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.	BTK
34861696	10.1182/bloodadvances.2021006211	Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.	BTK
34861036	10.1182/blood.2021014085	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.	BTK
34858810	10.3389/fonc.2021.720704	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.	BTK
34858727	10.1080/2162402X.2021.2003533	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.	BTK
34843717	10.1016/j.bcp.2021.114861	Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα.	BTK
34839996	10.1016/j.ejmech.2021.114009	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.	BTK
34838186	10.1016/j.ccell.2021.11.006	Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.	BTK
34821081	10.1002/cnr2.1590	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.	BTK
34817087	10.1002/hon.2952	Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era.	BTK
34795418	10.1038/s41375-021-01470-4	Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.	BTK
34783281	10.1080/10428194.2021.1999444	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.	BTK
34778802	10.1158/2643-3230.BCD-21-0063	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.	BTK
34774461	10.1016/j.clml.2021.09.012	SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?	BTK
34771616	10.3390/cancers13215453	Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia.	BTK
34771535	10.3390/cancers13215372	Update on Novel Therapeutics for Primary CNS Lymphoma.	BTK
34750354	10.1038/s41419-021-04353-9	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.	BTK
34739844	10.1016/j.ccell.2021.10.006	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	BTK
34733270	10.3389/fimmu.2021.703256	Cytomegalovirus in Haematological Tumours.	BTK
34732441	10.21873/anticanres.15384	Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.	BTK
34724705	10.1182/bloodadvances.2021005621	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.	BTK
34722279	10.3389/fonc.2021.733848	Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.	BTK
34714908	10.1182/bloodadvances.2021005486	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	BTK
34713475	10.1002/hon.2943	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.	BTK
34710755	10.1016/j.phymed.2021.153802	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.	BTK
34679161	10.1182/blood.2021013326	Therapeutic options for relapsed/refractory mantle cell lymphoma.	BTK
34667996	10.21037/aol-20-20	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	BTK
34651869	10.1002/hon.2933	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	BTK
34638136	10.1182/bloodadvances.2020003698	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.	BTK
34626359	10.1007/978-3-030-78311-2_8	Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.	BTK
34625994	10.1002/ajh.26367	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.	BTK
34615723	10.1158/1078-0432.CCR-21-2183	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.	BTK
34606736	10.1080/14728222.2021.1988927	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.	BTK
34599723	10.1007/s11899-021-00645-1	BTK Inhibitors in Chronic Lymphocytic Leukemia.	BTK
34557659	10.1016/j.isci.2021.102931	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	BTK
34551904	10.1158/1078-0432.CCR-21-1067	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.	BTK
34534359	10.1111/imm.13416	The role of Bruton's tyrosine kinase in the immune system and disease.	BTK
34509879	10.1016/j.ejmech.2021.113820	Discovery of novel BTK PROTACs for B-Cell lymphomas.	BTK
34508613	10.18632/aging.203314	Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.	BTK
34500472	10.1182/bloodadvances.2021004528	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.	BTK
34497201	10.11406/rinketsu.62.1139	[Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].	BTK
34497195	10.11406/rinketsu.62.1085	[Molecular pathogenesis and treatment of chronic lymphocytic leukemia].	BTK
34491123	10.1080/17512433.2021.1978288	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.	BTK
34478505	10.1182/bloodadvances.2021005083	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.	BTK
34474146	10.1016/j.exphem.2021.08.010	miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.	BTK
34447768	10.3389/fmed.2021.708071	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.	BTK
34414843	10.1080/10428194.2021.1964020	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.	BTK
34332791	10.1016/j.pathol.2021.04.008	Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.	BTK
34327825	10.1111/jth.15367	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.	BTK
34323286	10.1002/eji.202048968	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.	BTK
34320163	10.1182/blood.2020006783	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.	BTK
34319003	10.1002/cnr2.1524	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.	BTK
34314938	10.1016/j.bmc.2021.116275	Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.	BTK
34293088	10.1182/blood.2021012039	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.	BTK
34281758	10.1016/j.clml.2021.06.017	A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.	BTK
34280258	10.1182/blood.2021011787	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.	BTK
34277452	10.3389/fonc.2021.707285	Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.	BTK
34269152	10.1080/10428194.2021.1938027	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.	BTK
34268530	10.1358/dot.2021.57.7.3285932	An update on acalabrutinib to treat chronic lymphocytic leukemia.	BTK
34264564	10.20892/j.issn.2095-3941.2020.0291	SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.	BTK
34263144	10.1097/HS9.0000000000000620	The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.	BTK
34249912	10.3389/fcell.2021.655489	Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.	BTK
34248972	10.3389/fimmu.2021.687458	Targeting Bruton's Tyrosine Kinase in CLL.	BTK
34214199	10.1111/ejh.13682	MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.	BTK
34185336	10.1002/ajh.26284	BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.	BTK
34177947	10.3389/fimmu.2021.689472	Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.	BTK
34174984	10.1016/j.hoc.2021.04.001	The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.	BTK
34174847	10.1186/s12885-021-08475-3	Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.	BTK
34170207	10.1080/17474086.2021.1947236	Managing complications secondary to Waldenström's macroglobulinemia.	BTK
34159878	10.1080/10428194.2021.1929961	Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.	BTK
34137347	10.1080/14740338.2021.1945031	Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation.	BTK
34132782	10.1182/blood.2021011405	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.	BTK
34123480	10.6004/jadpro.2021.12.4.8	A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.	BTK
34120550	10.1080/14656566.2021.1941864	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.	BTK
34108321	10.11406/rinketsu.62.398	[Development and prospects of molecular targeted agents for malignant lymphoma].	BTK
34100025	10.1101/2021.06.02.21257804	Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.	BTK
34063667	10.3390/cancers13092198	Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.	BTK
34055635	10.3389/fonc.2021.668162	Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.	BTK
34021874	10.1007/s11899-021-00637-1	Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.	BTK
34012272	10.2147/OTT.S300805	Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report.	BTK
34000704	10.1016/j.bioorg.2021.104968	Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.	BTK
33996600	10.3389/fonc.2021.672052	Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.	BTK
33981831	10.1016/j.omto.2021.03.015	Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.	BTK
33946867	10.3390/cancers13092146	Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.	BTK
33912812	10.1097/HS9.0000000000000564	Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.	BTK
33902692	10.1186/s40164-021-00222-5	Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.	BTK
33902665	10.1186/s13045-021-01054-w	Current and future treatment strategies in chronic lymphocytic leukemia.	BTK
33896333	10.1080/10428194.2021.1913139	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.	BTK
33869054	10.3389/fonc.2021.651057	Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.	BTK
33851691	10.1358/dot.2021.57.4.3264113	Tirabrutinib hydrochloride for B-cell lymphomas.	BTK
33827598	10.1186/s12935-021-01891-2	Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.	BTK
33812443	10.19746/j.cnki.issn.1009-2137.2021.02.052	[New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].	BTK
33775465	10.1016/j.blre.2021.100824	Revisiting Richter transformation in the era of novel CLL agents.	BTK
33740548	10.1016/j.ejmech.2021.113329	Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.	BTK
33735664	10.1016/j.neo.2021.02.002	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.	BTK
33730585	10.1016/j.celrep.2021.108870	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.	BTK
33718939	10.12703/r/10-22	Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.	BTK
33711241	10.1080/14656566.2021.1902988	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.	BTK
33704654	10.1007/s40265-021-01482-5	Orelabrutinib: First Approval.	BTK
33688166	10.2147/DDDT.S250823	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.	BTK
33676628	10.1016/S0140-6736(21)00224-5	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.	BTK
33663302	10.1080/10428194.2021.1894643	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.	BTK
33645373	10.1080/14740338.2021.1897565	Reducing treatment toxicity in Waldenström macroglobulinemia.	BTK
33639170	10.1016/j.jbc.2021.100465	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	BTK
33629212	10.1007/s12032-021-01470-5	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	BTK
33613932	10.1177/2040620721990553	The role of acalabrutinib in adults with chronic lymphocytic leukemia.	BTK
33599764	10.1182/blood.2020009781	Building on BTK inhibition in MCL.	BTK
33579791	10.1158/1078-0432.CCR-21-0140	A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.	BTK
33570649	10.1182/bloodadvances.2020003423	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.	BTK
33569985	10.1080/10428194.2021.1881514	Clinical application of genomics in Waldenström macroglobulinemia.	BTK
33566715	10.1080/14712598.2021.1889510	Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.	BTK
33552659	10.6004/jadpro.2021.12.1.2	Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia.	BTK
33531153	10.1016/j.bulcan.2020.12.006	[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].	BTK
33515702	10.1016/j.critrevonc.2021.103238	Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis.	BTK
33512408	10.1182/blood.2020005964	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.	BTK
33489445		Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.	BTK
33477957	10.3390/cancers13020354	Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells.	BTK
33463471	10.2174/1568026621666210119112336	A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.	BTK
33427570	10.1080/10428194.2020.1864352	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.	BTK
33426371	10.1016/j.bioactmat.2020.12.010	The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.	BTK
33419778	10.1158/1078-0432.CCR-20-3741	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.	BTK
33380880	10.3747/co.27.6795	Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.	BTK
33340912	10.1016/j.ejmech.2020.113094	1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase.	BTK
33306268	10.1111/cts.12948	Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.	BTK
33297772	10.1080/17474086.2020.1851184	Zanubrutinib for the treatment of Waldenström Macroglobulinemia.	BTK
33288483	10.1016/j.clml.2020.10.015	Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.	BTK
33287742	10.1186/s12885-020-07678-4	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.	BTK
33275726	10.1182/hematology.2020000121	Management of Waldenström macroglobulinemia in 2020.	BTK
33273169	10.1212/CON.0000000000000936	Central Nervous System Lymphomas.	BTK
33272709	10.1016/j.bioorg.2020.104385	Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.	BTK
33263441	10.1080/17474086.2021.1856652	Development of molecular intervention strategies for B-cell lymphoma.	BTK
33226337	10.7554/eLife.60470	Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.	BTK
33216986	10.1111/bjh.17184	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.	BTK
33214835	10.1021/acsmedchemlett.0c00378	Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.	BTK
33199185	10.1016/j.clml.2020.10.012	Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.	BTK
33188997	10.1016/j.ctarc.2020.100235	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	BTK
33154951	10.3389/fonc.2020.591577	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	BTK
33152104	10.1111/bjh.17197	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.	BTK
33140664	10.1080/10428194.2020.1832660	Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).	BTK
33134182	10.3389/fonc.2020.592205	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?	BTK
33128020	10.1038/s41375-020-01074-4	Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.	BTK
33127325	10.1016/j.clml.2020.10.007	Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.	BTK
33126415	10.3390/ijms21218006	Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.	BTK
35117332	10.21037/tcr-20-72	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.	BTK
33109547	10.21873/anticanres.14630	Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.	BTK
33093947	10.12688/f1000research.22318.1	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.	BTK
33091850	10.1016/j.bmc.2020.115815	Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.	BTK
33091668	10.1016/j.bioorg.2020.104377	HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.	BTK
33091356	10.1016/S2352-3026(20)30224-6	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.	BTK
33089525	10.1111/ejh.13538	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.	BTK
33068336	10.1002/cam4.3499	Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.	BTK
33025948	10.1358/dot.2020.56.8.3158047	Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.	BTK
33020271	10.1073/pnas.2007946117	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	BTK
33011863	10.1007/s00428-020-02937-y	ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.	BTK
33005100	10.1186/s12935-020-01518-y	Ibrutinib in B-cell lymphoma: single fighter might be enough?	BTK
32985902	10.2217/fon-2020-0794	A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.	BTK
32955949	10.1080/14728214.2020.1822816	Emerging drugs for the treatment of Waldenström macroglobulinemia.	BTK
32929063	10.1038/s41392-020-00309-1	Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma.	BTK
32926124	10.1182/bloodadvances.2020001685	Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.	BTK
32899476	10.3390/cancers12092525	Relevant Cytokines in the B Cell Lymphoma Micro-Environment.	BTK
32869675	10.1080/17474086.2020.1817735	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.	BTK
32864130	10.1186/s40364-020-00214-3	A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.	BTK
32862863	10.1016/S2152-2650(20)30456-0	Waldenström Macroglobulinemia - 2020 Update on Management and Future Directions.	BTK
32862855	10.1016/S2152-2650(20)30449-3	BTK Inhibitors and Chemoimmunotherapy for CLL.	BTK
32861288	10.1016/j.hoc.2020.06.009	Blastoid Mantle Cell Lymphoma.	BTK
32861287	10.1016/j.hoc.2020.06.008	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?	BTK
32861286	10.1016/j.hoc.2020.06.007	Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.	BTK
32855532	10.1038/s41401-020-00505-3	Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.	BTK
32848159	10.1038/s41467-020-17997-6	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry.	BTK
32824276	10.3390/cancers12082303	Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.	BTK
32753893	10.2147/OTT.S238832	Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date.	BTK
32731259	10.1182/blood.2020006844	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.	BTK
32715803	10.1080/14740338.2020.1802424	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.	BTK
32698195	10.1182/blood.2020006449	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.	BTK
32691208	10.1007/s11060-020-03580-y	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.	BTK
32683672	10.1002/ijc.33212	Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.	BTK
32677095	10.1111/bjh.16946	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.	BTK
32644193	10.1002/cncr.33058	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.	BTK
32643971	10.1177/0300060520936053	Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.	BTK
32631091	10.1080/14737140.2020.1791705	The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.	BTK
32613545	10.1007/s40257-020-00535-x	Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.	BTK
32603202	10.1080/14656566.2020.1770727	An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.	BTK
32598477	10.1182/bloodadvances.2019001350	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	BTK
32586008	10.3390/biomedicines8060170	ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.	BTK
32585766	10.1002/1878-0261.12753	Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.	BTK
32582577	10.2147/ITT.S240874	Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?	BTK
32563910	10.1016/j.tranon.2020.100817	Ibrutinib is not an effective drug in primografts of TCF3-PBX1.	BTK
32552760	10.1186/s13045-020-00914-1	Emerging therapies in mantle cell lymphoma.	BTK
32519423	10.1002/1878-0261.12742	Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.	BTK
32508208	10.1080/10428194.2020.1772477	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.	BTK
32489274	10.3747/co.27.6291	Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia.	BTK
32484067	10.1177/1091581820918511	Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor.	BTK
32481736	10.3390/cancers12061396	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.	BTK
32461234	10.1158/1078-0432.CCR-19-3703	Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.	BTK
32455989	10.3390/cancers12051328	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.	BTK
32452526	10.1111/bjh.16759	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.	BTK
32420699	10.1002/cam4.3136	Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.	BTK
32415780	10.1111/bjh.16738	Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.	BTK
32400331	10.2174/1389557520666200513121524	Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.	BTK
32393328	10.1186/s13045-020-00884-4	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.	BTK
32385234	10.1038/s41467-020-16128-5	Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.	BTK
32382949	10.1007/s40265-020-01318-8	Tirabrutinib: First Approval.	BTK
32370190	10.3390/cancers12051143	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.	BTK
32345646	10.1158/1078-0432.CCR-20-1427	BTK Inhibitors in Cancer Patients with COVID-19: ""The Winner Will be the One Who Controls That Chaos"" (Napoleon Bonaparte).	BTK
32333154	10.1007/s00277-020-04005-6	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.	BTK
32321318	10.1080/13543784.2020.1760245	Novel agents for mantle cell lymphoma: molecular rational and clinical data.	BTK
32306816	10.1080/10428194.2020.1753043	The effect of ibrutinib on neutrophil and γδ T cell functions.	BTK
32292084	10.1080/14656566.2020.1751123	Duvelisib for the treatment of chronic lymphocytic leukemia.	BTK
32253666	10.1007/s12185-020-02867-0	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?	BTK
32242358	10.1056/NEJMoa1914347	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.	BTK
32239765	10.1002/ajh.25796	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	BTK
32209572	10.1158/1078-0432.CCR-19-2856	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.	BTK
32207333	10.2217/fon-2019-0844	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.	BTK
32198151	10.1158/1078-0432.CCR-19-3815	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.	BTK
32197990	10.1016/j.clml.2020.02.001	Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.	BTK
32186759	10.3892/mmr.2020.11022	PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.	BTK
32168755	10.3390/cancers12030650	Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment.	BTK
32162560	10.1080/14656566.2020.1737010	Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.	BTK
32127939	10.7150/jca.34981	Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma <i>in vivo and vitro</i>.	BTK
32127472	10.1073/pnas.1921187117	Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.	BTK
32114502	10.1136/jitc-2020-000587	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.	BTK
32103491	10.1111/bjh.16463	Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.	BTK
32093809	10.3727/096504020X15825405463920	A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.	BTK
32083995	10.1200/JCO.19.02314	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.	BTK
32064588	10.1111/bjh.16407	Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.	BTK
32027299	10.19746/j.cnki.issn.1009-2137.2020.01.056	[Reaserch Advance on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Tumors--Review].	BTK
32017058	10.1111/bjh.16406	The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.	BTK
32014679	10.1016/j.ejmech.2020.112092	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.	BTK
32011729	10.1111/bjh.16416	Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.	BTK
32006301	10.1007/s11899-020-00559-4	Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.	BTK
32005797	10.1038/s41408-020-0277-6	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.	BTK
31992103	10.1080/10428194.2020.1719100	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.	BTK
31933167	10.1007/s40265-019-01252-4	Zanubrutinib: First Approval.	BTK
31931656	10.1080/15384047.2019.1700743	Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.	BTK
31918398	10.1016/j.bioorg.2019.103542	JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.	BTK
31876911	10.1182/blood.2018884940	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.	BTK
31866281	10.1016/S2352-3026(19)30210-8	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.	BTK
31865062	10.1016/j.leukres.2019.106286	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.	BTK
31862225	10.1016/j.jocn.2019.11.013	Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature.	BTK
31831562	10.1158/1078-0432.CCR-19-2202	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.	BTK
31808904	10.1182/hematology.2019001321	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.	BTK
31806993	10.2147/OTT.S227122	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	BTK
31801949	10.1038/s41419-019-2158-0	Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.	BTK
31782972	10.1002/hon.2694	New responsibilities for aged kinases in B-lymphomas.	BTK
31772331	10.1038/s41388-019-1122-x	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.	BTK
31766355	10.3390/cancers11121834	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.	BTK
31764119	10.1097/PPO.0000000000000412	Bruton Tyrosine Kinase Inhibitors: Present and Future.	BTK
31738609	10.1080/14656566.2019.1689959	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.	BTK
31723816	10.1097/HS9.0000000000000175	From Biology to Therapy: The CLL Success Story.	BTK
31708654	10.3747/co.26.4957	Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.	BTK
31699465	10.1016/j.blre.2019.100635	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.	BTK
31699386	10.1016/j.bioorg.2019.103361	New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.	BTK
31688198	10.1097/QCO.0000000000000611	Azole antifungals and new targeted therapies for hematological malignancy.	BTK
31686856	10.2147/OTT.S155778	Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.	BTK
31685258	10.1016/j.bioorg.2019.103367	Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.	BTK
31676565	10.1158/2159-8290.CD-19-1135	Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.	BTK
31648477	10.3760/cma.j.issn.0253-2727.2019.09.008	[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].	BTK
31638169	10.3892/or.2019.7364	Ibrutinib in CLL/SLL: From bench to bedside (Review).	BTK
31628288	10.3171/2019.7.JNS191376	Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.	BTK
31624617	10.1002/ccr3.2257	Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review.	BTK
31619091	10.1080/17474086.2020.1681962	Contemporary management of nodal and primary splenic marginal zone lymphoma.	BTK
31591468	10.1038/s41375-019-0592-8	What is new in the treatment of Waldenstrom macroglobulinemia?	BTK
31558766	10.1038/s41375-019-0575-9	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.	BTK
31534006	10.4049/jimmunol.1801327	Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.	BTK
31527073	10.1182/blood.2019000725	How I treat Waldenström macroglobulinemia.	BTK
31511358	10.4049/jimmunol.1900321	Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.	BTK
31508518	10.1016/j.heliyon.2019.e02290	Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.	BTK
31481959	10.3389/fimmu.2019.01953	A Novel <i>BTK</i> Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.	BTK
31468508	10.1111/bjh.16168	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.	BTK
31443360	10.3390/pathogens8030129	Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment.	BTK
31432184	10.3892/or.2019.7282	Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.	BTK
31420873	10.1002/hon.2667	The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.	BTK
31406628	10.1186/s40164-019-0141-1	Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.	BTK
31395509	10.1016/j.bmc.2019.07.043	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.	BTK
31384539	10.1016/j.apsb.2019.01.001	Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).	BTK
31382969	10.1186/s12964-019-0391-x	Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.	BTK
31364164	10.1111/bph.14809	A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk<sup>C481S</sup> mutation in B-cell malignancies.	BTK
31355927	10.1111/bjh.16118	Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.	BTK
31340982	10.1182/blood.2019001160	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.	BTK
31327069	10.1007/s11912-019-0819-x	How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.	BTK
31316181	10.1038/s41401-019-0250-8	Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.	BTK
31296529	10.1158/1078-0432.CCR-19-0273	Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.	BTK
31286638	10.1111/vco.12520	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.	BTK
31257351	10.3960/jslrt.19006	Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.	BTK
31234030	10.1016/j.ejmech.2019.06.035	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.	BTK
31233483	10.1097/CCO.0000000000000556	Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.	BTK
31229160	10.1016/j.hoc.2019.03.004	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.	BTK
31227358	10.1016/j.clml.2019.05.008	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.	BTK
31217352	10.1172/jci.insight.127566	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.	BTK
31189540	10.1136/jclinpath-2019-205837	Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.	BTK
31188814		Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.	BTK
31187531	10.1002/hon.2596	The modern approach to mantle cell lymphoma.	BTK
31171645	10.3324/haematol.2019.220590	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.	BTK
31123343	10.1038/s41375-019-0489-6	PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.	BTK
31109313	10.1186/s12885-019-5717-y	The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.	BTK
31105705	10.3389/fimmu.2019.00895	Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for <i>TP53</i> Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia.	BTK
31068044	10.1080/10428194.2019.1608536	Hairy cell leukemia: present and future directions.	BTK
31043832	10.3747/co.26.4345	Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.	BTK
31031018	10.1016/j.bioorg.2019.102943	Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.	BTK
30999237	10.1016/j.ejmech.2019.03.055	Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).	BTK
30963600	10.1002/ajh.25487	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.	BTK
30940906	10.1038/s41375-019-0463-3	CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.	BTK
30927175	10.1007/s11523-019-00635-7	Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.	BTK
30916599	10.1080/17474086.2019.1597703	Ibrutinib for the treatment of chronic lymphocytic leukemia.	BTK
30907011	10.1002/cbf.3381	TAK1 is a druggable kinase for diffuse large B-cell lymphoma.	BTK
30888232	10.1080/13543776.2019.1594777	Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).	BTK
30887112	10.1007/s00109-019-01777-x	Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.	BTK
30884247	10.1080/17474086.2019.1596793	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma.	BTK
30878129	10.1016/j.critrevonc.2019.02.001	Management of adverse effects/toxicity of ibrutinib.	BTK
30875504	10.1016/j.ejmech.2019.02.077	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.	BTK
30872780	10.1038/s41375-019-0442-8	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	BTK
30862686	10.1158/1541-7786.MCR-18-0256	Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.	BTK
30858551	10.1038/s41375-019-0440-x	Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.	BTK
30857748	10.1016/j.bmcl.2019.03.005	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.	BTK
30843894		Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.	BTK
30821551	10.1080/10428194.2019.1569231	Modulation of immune checkpoint molecule expression in mantle cell lymphoma.	BTK
30819916	10.3324/haematol.2018.212811	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.	BTK
34468365	10.1158/2159-8290.CD-RW2019-016	Ibrutinib plus Palbociclib Has Efficacy in Mantle Cell Lymphoma.	BTK
30791947	10.1186/s40425-019-0529-9	A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.	BTK
30788082	10.1016/j.csbj.2019.01.006	Bivalent Ligands for Protein Degradation in Drug Discovery.	BTK
30777096	10.1186/s13046-019-1076-4	Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.	BTK
30760464	10.1182/bloodadvances.2018029058	Resistance mechanism for ibrutinib in marginal zone lymphoma.	BTK
30723172	10.1126/scisignal.aat4105	Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.	BTK
30719267	10.1177/2040620718820510	Novel treatment approaches and future perspectives in follicular lymphoma.	BTK
30706214	10.1007/s12272-019-01124-1	Development of BTK inhibitors for the treatment of B-cell malignancies.	BTK
30700840	10.1038/s41375-018-0366-8	New roles for B cell receptor associated kinases: when the B cell is not the target.	BTK
30693983	10.1002/mc.22983	The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.	BTK
30692121	10.1182/blood-2018-11-886457	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.	BTK
30681658		In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.	BTK
30679329	10.3324/haematol.2018.214759	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.	BTK
30638402	10.1080/17512433.2019.1568868	Acalabrutinib for adults with mantle cell lymphoma.	BTK
30567753	10.1182/blood-2018-09-875732	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.	BTK
30556110	10.1007/s40262-018-0725-7	Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.	BTK
30546948	10.1080/2162402X.2018.1512455	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,<i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.	BTK
30545835	10.1182/blood-2018-07-862953	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.	BTK
30522954	10.1016/j.bmcl.2018.11.051	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.	BTK
30534553	10.1155/2018/1042597	Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.	BTK
30508305	10.1002/cncr.31831	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.	BTK
30510142	10.1158/1535-7163.MCT-17-0789-ATR	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.	BTK
30453157	10.1016/j.jpba.2018.11.012	Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.	BTK
30442651	10.1124/dmd.118.084459	Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.	BTK
30423172	10.1093/neuonc/noy193	Introduction of novel agents in the treatment of primary CNS lymphoma.	BTK
30413649	10.1158/1535-7163.MCT-18-0478	Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.	BTK
30401751	10.1182/bloodadvances.2018022962	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.	BTK
30390220	10.1007/s40265-018-1003-6	Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.	BTK
30381956	10.2217/fon-2018-0637	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.	BTK
30305939	10.1136/esmoopen-2018-000387	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.	BTK
30280589	10.1080/1062936X.2018.1518927	Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.	BTK
30277101	10.1080/10428194.2018.1512710	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.	BTK
30231317	10.1200/EDBK_200829	Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.	BTK
30209121	10.1182/blood-2018-03-841015	B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.	BTK
30190023	10.1016/j.hoc.2018.05.012	First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.	BTK
30175400	10.1111/bjh.15567	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.	BTK
30115641	10.1182/bloodadvances.2018016048	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.	BTK
30104685	10.1038/s41598-018-30509-3	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.	BTK
30077698	10.1016/j.clml.2018.07.287	Risk of Major Bleeding with Ibrutinib.	BTK
30077608	10.1016/j.bmc.2018.07.047	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ.	BTK
30072003	10.1016/j.jacc.2018.06.002	Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.	BTK
30069629	10.1007/978-3-319-91439-8_7	Ibrutinib.	BTK
30052472	10.1080/17474086.2018.1506327	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?	BTK
30029202	10.1016/j.jchromb.2018.06.026	Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.	BTK
30013190	10.1038/s41388-018-0397-7	Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.	BTK
30011241	10.1177/2472555218786165	Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.	BTK
30006143	10.1016/j.bmc.2018.07.007	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.	BTK
29978754	10.1080/10428194.2018.1480775	Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.	BTK
29925955	10.1038/s41586-018-0290-0	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	BTK
29912596	10.1080/10428194.2018.1457148	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.	BTK
29899297	10.3390/ijms19061758	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	BTK
29875397	10.1038/s41422-018-0055-1	PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.	BTK
29873072	10.1111/bjh.15421	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.	BTK
29861875	10.18632/oncotarget.25011	The B cell receptor signaling pathway in mantle cell lymphoma.	BTK
29855199	10.1080/13543784.2018.1482273	Targeting the B cell receptor pathway in non-Hodgkin lymphoma.	BTK
29808236	10.1007/s11864-018-0548-7	Pitfalls of Combining Novel Agents in Lymphoma.	BTK
29785709	10.1111/bjh.15411	Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).	BTK
29781323	10.1080/14728214.2018.1479396	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.	BTK
29768934	10.1080/14740338.2018.1477936	A safety profile of medications used to treat Waldenström's macroglobulinemia.	BTK
29741794	10.1002/ardp.201700369	Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.	BTK
29740811	10.1111/bjh.15271	Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.	BTK
29737219	10.1080/17474086.2018.1473030	Use of acalabrutinib in patients with mantle cell lymphoma.	BTK
29735551	10.1158/0008-5472.CAN-17-4004	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	BTK
29725548	10.1155/2018/5471368	A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.	BTK
29721381	10.1080/2162402X.2017.1423183	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.	BTK
29715023	10.1021/acs.jmedchem.8b00441	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.	BTK
29712895	10.1038/s41408-018-0076-5	Waldenström macroglobulinemia treatment algorithm 2018.	BTK
29690649	10.3390/cancers10040127	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.	BTK
29669753	10.1182/bloodadvances.2017011916	Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.	BTK
29652138	10.1021/acs.bioconjchem.8b00137	Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells.	BTK
29637541	10.1111/bjh.15202	How we manage patients with Waldenström macroglobulinaemia.	BTK
29615403	10.1182/blood-2018-02-832535	SOX11 augments BCR signaling to drive MCL-like tumor development.	BTK
29590547	10.1056/NEJMoa1715519	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.	BTK
29567799	10.1182/blood-2017-10-809210	Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.	BTK
29560128	10.18632/oncotarget.24310	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.	BTK
29549872	10.1016/j.ctrv.2018.01.002	Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.	BTK
29532266	10.1007/s10753-018-0745-3	Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation.	BTK
29496671	10.1182/blood-2017-10-811752	BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanism.	BTK
29484684	10.1002/hon.2502	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.	BTK
29483358	10.4049/jimmunol.1701489	Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.	BTK
29483220	10.1158/1535-7163.MCT-17-0784	p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.	BTK
29476222	10.1007/s00280-018-3546-3	Ibrutinib brain distribution: a preclinical study.	BTK
29472356	10.3324/haematol.2017.184325	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.	BTK
29455639	10.1186/s12943-018-0779-z	Role of Bruton's tyrosine kinase in B cells and malignancies.	BTK
29452660	10.1016/j.beha.2017.10.010	Novel therapies for relapsed/refractory mantle cell lymphoma.	BTK
25944695	10.18632/oncotarget.3824	Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.	BTK
25433814	10.1007/s00428-014-1698-z	Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.	BTK
25189416	10.1038/leu.2014.263	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	BTK
24658273	10.1038/nrc3702	Targeting Bruton's tyrosine kinase in B cell malignancies.	BTK
23581641	10.3109/10428194.2013.794458	Bruton's tyrosine kinase: potential target in human multiple myeloma.	BTK
18241233	10.1111/j.1365-2249.2008.03589.x	Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model.	BTK
16141323	10.1073/pnas.0505196102	Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.	BTK
15939795	10.1084/jem.20042101	Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.	BTK
12854903	10.1080/1042819031000067576	Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.	BTK
11920564	10.1002/1521-4141(200204)32:4&lt;982::AID-IMMU982&gt;3.0.CO;2-I	Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays.	BTK
35196427	10.1056/NEJMoa2114110	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.	BTK
8688094	10.1126/science.273.5278.1096	BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells.	BTK
8283037		Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.	BTK
33419778	10.1158/1078-0432.CCR-20-3741	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.	BTK
30940906	10.1038/s41375-019-0463-3	CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.	BTK
30872780	10.1038/s41375-019-0442-8	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	BTK
28428442	10.1158/1535-7163.MCT-16-0555	Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.	BTK
27157620	10.1038/onc.2016.155	FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.	BTK
26961147	10.1093/annonc/mdw131	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.	BTK
24970801	10.18632/oncotarget.2071	Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.	BTK
23977012	10.1371/journal.pone.0071302	Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.	BTK
19212330	10.1038/leu.2009.23	Identification of a Btk-BAG3 complex induced by oxidative stress.	BTK
31801949	10.1038/s41419-019-2158-0	Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.	BTK
31534006	10.4049/jimmunol.1801327	Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.	BTK
30887112	10.1007/s00109-019-01777-x	Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.	BTK
26540570	10.18632/oncotarget.6273	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.	BTK
25284608	10.1111/bjh.13149	Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.	BTK
10498607		Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.	BTK
10068673		Involvement of wiskott-aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway.	BTK
8892607		Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways.	BTK
